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One of the biggest challenges in tissue engineering currently is the formation of a 
functional microvascular network as part of an engineered tissue graft. Despite many 
advances in tissue engineering methods, the field still awaits biograft designs that enable 
neovascularization at clinically relevant size scales. Critical to the design of such 
materials are tissue-specific physico-mechanical properties and controlled local 
therapeutic molecular release.  
 The purpose of the current research is to develop such a multifunctional biograft 
material from type I collagen polymers. Although collagen-based biomaterials have been 
applied broadly to tissue engineering and local drug delivery applications, persistent 
shortcomings remain, including poor mechanical properties, rapid proteolytic 
degradation, and cursory control over physical properties and molecular release profiles. 
In large part, this is owing to 1) poor characterization of conventional formulations in 
terms of their molecular composition and 2) inability to fully capitalize on the inherent 
self-assembly or polymerization capacity of collagen.  
Here we address current shortcomings through the development of self-assembling, 
collagen-fibril biograft materials through integrated tissue engineering and molecular 
delivery design. More specifically, collagen polymers specified by their intermolecular 
crosslink composition and self-assembly capacity were used to customize and design 
materials in terms of 1) collagen fibril microstructure and 2) proteolytic degradability, 
collectively defining overall local molecular release profiles. Application of the designed 
collagen biograft materials to control vascular endothelial growth factor (VEGF) release 
for promoting neovascularization and tissue regeneration was shown using an established 
in-vivo chicken egg chorioallantoic membrane (CAM) model. 
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 Results indicated that the collagen polymers specified by their intermolecular 
crosslink composition and self-assembly capacity can be used effectively to fashion a 
broad range of multifunctional collagen-fibril biograft materials with tunable physical 
and molecular delivery properties in absence of excessive processing and exogenous 
crosslinking. Further, using heparin affinity-based VEGF retention in collagen constructs, 
we demonstrated improved and accelerated neovascularization as well as cellularization 
of the collagen biografts implanted on CAM. These highly porous collagen materials 
comprise D-banded fibrils, resembling those found in tissues, and maintain their inherent 
biological signaling properties, thereby providing an ideal platform for integrated tissue 




CHAPTER 1. INTRODUCTION 
Soft tissue reconstruction is often required as a result of trauma, burns, tumor resection, 
congenital defects, and chronic wounds.  Unfortunately, the lack or limited supply of 
autograft tissues remains a major surgical challenge[1]. While various types of scaffolds 
prepared from synthetic or natural materials have been used for simple reconstruction, 
their effectiveness remains limited by slow neovascularization ultimately contributing to 
poor functional integration, pain, and/or scarring. An ideal solution for clinicians would 
be a designer biologic graft material that provides appropriate multi-scale structure and 
function while fostering rapid vascularization for improved tissue integration and 
regeneration.  
Our long-term goal is to develop a multifunctional soft tissue graft material that provides 
1) tissue-specific physico-mechanical properties and 2) controlled, local therapeutic 
molecular release for accelerated neovascularization and functional tissue integration and 
regeneration.  Type I collagen, the predominant and major structural component of the 
ECM represents an ideal natural polymer candidate for such integrated tissue engineering 
and local molecular delivery strategies [2].  It possesses several advantages over other 
materials, such as inherent self-assembly and biological signaling capacities, proteolytic 
biodegradability, and low immunogenicity [3].   
Despite the advantages of collagen as a natural biomaterial, its application as a 
multifunctional delivery vehicle has been limited by the inability to precisely and 
predictably control its microstructure, mechanical properties, and proteolytic 
degradability [4, 5]. Shortcomings associated with conventional collagen-based drug 
delivery formulations include poor mechanical integrity, rapid proteolytic degradation, 
and burst release of molecules. Exogenous processing and crosslinking, including 
treatment with glutaraldehyde, polyepoxy compounds, or carbodiimides, are often used to 
slow down degradation and prolong the release of molecules [6-8]. Unfortunately, such 
strategies have been reported to have deleterious effects on the inherent biological 
signaling capacity of collagen resulting in adverse tissue responses [4, 9-13]. Thus, in 
order to harness the true potential of collagen as an ideal material for soft tissue repair 
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and regeneration, there is an urgent need to remedy shortcomings in existing collagen 
based formulations. 
We plan to address this gap through development of designer polymerizable collagen 
fibril matrices, capable of tunable therapeutic delivery, using self-assembling collagen 
building blocks. The advantage of using self-assembling material is that it provides 
ability to tailor specific bulk material properties, such as matrix stiffness, proteolytic 
degradability, release profiles, at a molecular level. Recently, the Voytik-Harbin 
laboratory has developed and characterized an uncommon set of collagen polymer 
building blocks that demonstrate such a self-assembly, and can be used in the hierarchical 
design and customization of collagen-fibril materials. These fundamental collagen 
molecule building blocks predictably and reproducibly control the relevant fibril- and 
matrix-level properties such as matrix pore size, permeability and diffusivity, stiffness, 
and cell-instructive signaling [14, 15]. The unique feature of this technology is that it 
capitalizes on the differential self-assembly or matrix-forming capacity of these collagen 
polymer building blocks.  Furthermore, no exogenous crosslinking is required to improve 
mechanical integrity or slow proteolytic degradation. As such, resultant materials display 
supramolecular fibril assemblies and biological signaling capacity inherent to in-vivo 
extracellular matrices.  
We now propose to extend this work by testing the central hypothesis that collagen 
polymer building blocks specified by their intermolecular crosslink composition and self-
assembly capacity can be used to modulate microstructure and proteolytic degradability 
of collagen-fibril materials to create functional soft tissue grafts with tunable molecular 
delivery, as illustrated in Figure 1. 
The objective  of the proposed work is to design and develop a self-assembling, 
multifunctional collagen graft material that supports accelerated vascularization and 
tissue integration and regeneration. 
We decided to accomplish our objective by pursuing the following AIMS: 
AIM 1: Design self-assembling collagen-based drug delivery system and define how its 
specific molecular and fibril level features modulate molecular release.  
AIM 2: Demonstrate application of self-assembled collagen graft materials towards 
enhancing local neovascularization in an in-vivo chorioallantoic membrane model 
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(CAM), through retention of heparin and vascular endothelial growth factor (VEGF) 
molecules.   
Figure 1: Schematics of design strategy for creating designer collagen biografts with 
tunable molecular delivery.The strategy to achieve a multi-functional collagen biograft 
from type I collagen is presented. It involves 1) modulation of collagen microstructure at 
molecular and fibrillar level and 2) altering proteolytic degradability of matrix, as both 
these parameters affect 1) solute/fluid transport and 2) cell fate and tissue formation. 
1.1 Background 
1.1.1 Motivation for applying collagen towards integrated tissue engineering and 
molecular delivery 
Chronic wounds, defined by the presence of a skin defect or lesion that persists longer 
than 6 weeks or has a frequent recurrence [16],  affect around 6.5 million patients in the 
United States alone [17], and as many as 37 million globally [18]. Chronic wounds pose a 
tremendous burden to the patients’ health as well as the economic system. An excess of 
US$25 billion is spent annually on treatment of chronic wounds, and the burden is 
escalating due to increasing health care costs, an aging population and a higher incidence 
of diabetes and obesity [19].  
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A common yet seriously challenging example of chronic wounds is a diabetic foot ulcer 
(DFU) which due to its suboptimal healing properties,  increases the risk of infection and 
if not cured in timely manner, leads to leg amputation [20]. In 2010, about 73,000 non-
traumatic lower-limb amputations were performed due to DFUs [21].  Costing $38,077 
per amputation procedure, approximately 3 billion dollars  are spent per year on diabetes-
related amputations [22].    An estimated 12% of individuals with a foot ulcer require foot 
amputation , which is a serious concern considering the fact that the 5-year survival rate 
after one major lower extremity amputation is about 50% [19].  
Chronic wounds fail to heal because of the disruption of the orderly sequence of events 
during the wound healing process. To understand pathophysiology of chronic wound, it is 
necessary to know the physiology of normal wound healing process first. Wound healing 
normally involves a complex interaction between epidermal and dermal cells, the 
extracellular matrix (ECM), angiogenesis, and plasma derived proteins, all coordinated 
through an array of cytokines and growth factors. This dynamic process can be classified 
into four overlapping phases, including hemostasis, inflammation, proliferation, and 
remodeling [23, 24], as depicted in Figure 2 and described briefly below. 
i) Hemostasis: After tissue injury, thrombus formation requires an interaction between 
endothelial cells, platelets, and coagulation factors to achieve hemostasis. Trapped 
platelets within the clot trigger an inflammatory response through the release of 
vasodilators, chemoattractants and activation of complement cascade.  
ii) Inflammation: In the early phase of inflammation, neutrophils predominate and 
remove bacteria and other foreign material from the wound by phagocytosis and release 
of enzymes. Later in the inflammatory phase neutrophils reduce in number and are 
replaced by macrophages. This stage lasts until about 48 h after injury.  
iii) Proliferation: In this phase, fibroblasts play an important role in the synthesis of new 
type I collagen and ECM. Additionally, tenascin, fibronectin, and proteoglycans are also 
produced. Production of ECM is clinically seen as formation of granulation tissue. The 
formation of new tissue combined with the contraction of surrounding tissues is essential 
for the healing of wounds. While new matrix is synthesized, existing matrix in and 
around the wound margin is degraded by several enzyme systems such as matrix 
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metalloproteinases (MMPs) and plasminogen activators. This stage occurs about 2–10 
days after injury. 
iv) Remodeling: In this phase, type I collagen replaces fibronectin, becoming the 
predominant ECM constituent and resulting in a more mature ECM. Once closure of the 
wound has been achieved, remodeling of the resulting scar occurs over months or years, 
with a reduction of cell content and blood flow in the scar tissue.  
 
Figure 2: Fundamental interrelation of the wound healing phases : Hemostasis (red), 
inflammation (blue), proliferation (green), and tissue remodeling (yellow). Figure 
adopted from [23]. 
An important feature of the proliferation phase in normal wound healing is 
neovascularization. The dynamic interactions between endothelial cells, various soluble 
angiogenic cytokines, and the ECM environment promote neovascularization in the 
wound as shown in Figure 3A [24]. Angiogenic capillaries sprout and invade the 
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fibrin/fibronectin-rich wound clot and organize into a microvascular network throughout 
the granulation tissue within a few days. 
 
Figure 3: Normal versus impaired wound healing. Normal wound healing (A) versus 
impaired wound healing (B). In a normal wound healing, fibroblasts construct new ECM 
necessary to support cell ingrowth, and blood vessels that carry oxygen and nutrients 
necessary for cell survival. The provisional ECM promotes granulation tissue formation. 
Macrophages, fibroblasts, and blood vessels move into the wound space as a unit, 
through dynamic biologic interactions contributing to tissue repair. Fibroblasts contribute 
to new type I collagen synthesis. While MMP levels decrease through the normal wound-
healing process, chronic wounds continue to show a significantly higher level of 
proteases and pro-inflammatory cytokines.  As a result, inflammation persists longer and 
higher levels of MMPs cause excessive breakdown of type I collagen and ECM. Chronic 
wound is healing is then further impaired by lack of neovascularization, and an impaired 
re-epithelialization. Figure adapted from [29]. 
However, in chronic wounds, this dynamic spatio-temporal interaction between 
endothelial cells, angiogenesis factors, and surrounding ECM proteins is impaired. The 
chronic skin defect is usually in a permanent inflammatory state due to a hyper stimulated 
neutrophil response[16].  Along with an elevated level of proinflammatory cytokines, 
permanent increased proteolytic activity is typical for chronic wounds,   contributed by 
excessive production of matrix metalloproteinases (MMPs) in the wound [25, 26]. MMPs 
are said to be responsible for poor healing by breaking down too many components of the 
ECM and by inhibiting growth factors that are essential for tissue synthesis [27]. This 
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imbalance between ECM deposition and degradation, and deficiencies in growth factor 
and cytokine receptors, lead to impaired progenitor cell recruitment and angiogenesis and 
delay wound epithelialization [28].  
Typically, wound debridement followed by its compression with sterile gauze is the 
classic treatment for treating acute wounds [30, 31]. However, when this method is not 
effective enough, chronic wounds have to be dressed with adequate biomaterials to 
protect the long-term healing from infection and aiding in tissue regeneration [31, 32].  
An intervention from alternative multifunctional tissue engineering strategy can therefore 
offer a potential solution, by providing a strong structural template for cell infiltration and 
growth of new tissue, and at the same time, providing local exposure of growth factors, 
that can coordinate angiogenic response for full functional tissue recovery. The ultimate 
goal for treating these wounds is scar-free healing and timely restoration of tissue 
function [33]. 
1.1.2 Collagen based materials as wound dressings available commercially 
As a major natural constituent of our body, collagen is seen to play an integral role in the 
repair and replacement of soft tissue by providing an extracellular scaffold, stimulating 
certain growth factors, and propagating tissue granulation [34]. As a result, numerous 
efforts have been put into developing collagen implants and wound dressings to 
specifically accelerate the natural process of wound healing and promote tissue 
regeneration. Variety of products have been commercially developed and reviewed in 
detail previously [34-40]. Selective examples of these products, including Oasis, 
Alloderm, and Integra Dermal Regeneration Template products are described below. It is 
claimed that the collagen in these products promotes the deposit of newly formed 
collagen in the wound bed. These dressings come in variety of formats, including pads, 
gels and particle forms. They can be used on surgical wounds, in deep wounds to fill dead 
space, to absorb exudate and to provide a moist environment.  
Alloderm (TM), distributed by the LifeCell Corporation, is a processed acellular dermal 
matrix derived from human cadavers [41]. Cadaveric tissue samples are first screened for 
a host of transmittable pathogens. The decellularization is achieved through use of 
detergent solution, that leaves only the dermal matrix and associated basal lamina intact, 
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removing all other cellular components [42]. Following decellularization, samples are 
lyophilized for storage, and must be rehydrated before use [43]. Upon grafting, host 
fibroblasts and associated vasculature infiltrates the Alloderm matrix. However, the full 
extent of vascularization is said to be uncertain [44, 45]. The clinical use of Alloderm 
also requires subsequent application of an ultrathin split-thickness autograft immediately 
following implantation, since Alloderm lacks an epidermal component and has limited 
barrier properties [44]. Other disadvantages of Alloderm are said to be requirement of 
multiple applications and a theoretical risk of transmission of human pathogens [46]. 
Oasis(TM), developed by Cook Biotech, is an acellular dermal scaffold derived from 
porcine small intestinal submucosa (SIS). It contains numerous dermal components 
including collagen, glycosaminoglycans (hyaluronic acid), proteoglycans, fibronectin, 
and bioactive growth factors such as fibroblast growth factor-2, transforming growth 
factor β1, and vascular endothelial growth factor (VEGF) present naturally in the SIS 
[47]. Following application to the wound bed, this acellular matrix is infiltrated by 
fibroblasts and associated vasculature, which gradually replace the material with new 
ECM components over time [48]. It should be noted that while the material has a limited 
porosity, it does not provide a moisture barrier and must be protected by an appropriate 
secondary dressing [49]. Oasis limitations therefore include possible higher infection rate, 
and  need for multiple applications [46]. Clinical data with Oasis is also limited. A 
clinical trial comparing the application of Oasis in 73 patients with diabetic foot ulcer 
showed only slight statistical superiority (p=0.055) when compared with Regranex - a 
carboxymethylcellulose-based topical gel containing recombinant human platelet-derived 
growth factor (rhPDGF-BB) [50] .  
Integra(TM) is a composite acellular collagen product developed by the Integra Life 
Science Corporation. It is composed of an outer layer of silicone and a cross-linked 
bovine type I collagen glycosaminoglycan dermal matrix and was originally described 
by Yannas and Burke [51, 52]. The collagen-GAG matrix is gradually invaded by host 
fibroblasts upon implantation in an  excised wound bed [44]. Tissue integration is said to 
take place in approximately 3-6 weeks, resulting in production of a 'neodermis' with 
associated vasculature [44]. During this time the silicone layer acts as a protective barrier, 
limiting moisture loss through the membrane [42]. Once the dermal layer regenerates, 
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the silicone layer has to be removed and the wound is permanently closed with a split 
thickness skin graft [34].  
While Integra has shown promise in the treatment of chronic wounds and burns, it has a 
number of limitations that hinder its clinical use. When compared with AlloDerm in a 
mouse wound model, the Integra matrix induced more foreign body response and giant 
cells, owing to the fact that it is a chemically cross-linked material [53]. Integra scaffold 
needs to be first cleared by macrophages in order to allow deposition of collagen 
fibers. Since Integra has no intrinsic immunological defenses, it can be easily infected by 
bacteria and requires daily monitoring for signs of bacterial growth until the bio 
integration process is complete [54]. In the incidence of infection, wound debridement 
and reapplication are typically necessary, which further lengthens the time required for 
healing [54]. Another concern is a two-step process required for Integra based therapy. 
Since the silicone layer of Integra functions only as a temporary covering, it must be 
replaced by an ultrathin autograft following neodermal formation [36]. Given that the 
average acceptance rate of Integra is at least 10% lower than for a standard split-thickness 
graft, patients might prefer to undergo the latter procedure directly instead of opting for a 
riskier two-step process, if they have sufficient donor skin [36]. Furthermore, technical 
difficulty in Integra application necessitates physician training, and as a result, it may 
only be used by practitioners that have undergone a company sponsored training program 
[55]. In an early trial, incidences of hematoma and seroma formation occurred due to  
improper application of Integra, highlighting the level of skill required for proper use of 
the material [52]. 
Thus, it is seen that despite the advantages of collagen based advanced wound dressings, 
undesirable outcomes limit the use of these products in treatment of chronic wound 
ulcers. In general, peripheral ischemia, which is a pathological characteristics of chronic 
ulcers, critically affects collagen based biomaterial transplantations [56, 57]. Many 
diabetic patients need surgical revascularization to achieve timely and durable healing. 
However, with collagen-based wound therapies, it currently takes 3-4 weeks for 
engineered dermal substitutes to be sufficiently vascularized, before a split-thickness skin 
graft can be placed on the neodermis [58]. Thus, slow vascularization along with the 
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inability of collagen based dressings to serve as stand-alone therapy adds to the 
current limitations of  collagen-based wound healing products, including frequent 
surgical interventions, high costs of treatment, and inflammation mediated response 
that leads to scar formation rather than tissue regeneration [34-39]. Thus, there is 
acute need to improve vascularization period, and tissue regeneration capacity of 
collagen-based products for clinical therapies.  
1.1.3 Drug delivery from conventional collagen formulations: state of the art 
To address the issue of slow vascularization and tissue regeneration through collagen 
based products, alternative of combining growth factors into collagen [59-61] has gained 
interest of researchers since many growth factors have been recently recognized as key 
signaling molecules inducing wound healing [28].  For example, platelet-derived growth 
factor-BB (PDGF-BB) is important for the granulation tissue formation and for stem cell 
recruitment, vascular endothelial growth factor-A (VEGF-A) is needed to induce blood 
vessel growth for sustaining the granulation tissue, and fibroblast growth factors (FGFs) 
are crucial for both wound reepithelization and angiogenesis [62]. However, none of 
these growth factor-loaded collagen matrices have reached commercial market as a 
treatment available to patients. The reasons could be associated with the rapid clearance 
from the matrix and/or degradation of soluble VEGF at the implant site [63, 64].  This 
raises an important question on the ability of collagen to serve as a matrix to achieve 
controlled release of growth factors. 
Interestingly, to date, numerous studies report applications of collagen for controlled drug 
delivery as ophthalmological shields, antibiotic-loaded sponges, drug loaded 
microspheres and  injectable collagen gels, and have been extensively reviewed 
previously [4, 5, 65, 66]. Select representative examples of these formulations reported in 
research articles are given in Appendix 1. Despite this wide research, close inspection 
shows that only a few collagen-based drug delivery formulations have made it into 
clinical trials or are currently marketed [4, 67, 68]. The selective examples of these 
commercially available products are given in Table 1. It was observed that the majority 
of these products are restricted to the delivery of an antimicrobial agent, silver (to prevent 
infection in chronic wounds), and ethylenediaminetetracetic acid (EDTA) (to form a 
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chelating complex with MMPs and to prevent them from excessively degrading matrix) 
[69]. Thus, despite the numerous advantages and wide research on collagen as an 
excellent natural biomaterial [4, 65, 67, 70, 71], its use as a vehicle for controlling local 
growth factor release is seen to be limited [72, 73]. This points to yet another gap in 
existing collagen based biomaterials - inability to achieve controlled release of 
biomolecules. 
Table 1: Examples of collagen based drug delivery products in market                               






Dressing format Application 
Cogenzia Innocoll Gentamicin Lyophilized sponge  Treatment of diabetic 
foot infections  
XaraColl Innocoll Bupivacaine 
Hydrochloride 
Local Anesthetic 
Sponge for   
postoperative pain 
relief 
Vitagel™  Orthovita 
Inc. 
Thrombin Suspension of 
bovine collagen and 





® Plus Ag 
Covalon EDTA and 
silver ions  
Lyophilized 
collagen sponge 
made with collagen, 
carboxyl methyl 
cellulose (CMC) 

















55% collagen and 
1% silver-ORC 
Healing chronic 









made from porcine 
type I collagen and 
gelatin  
Healing chronic 
wounds such as 





The scarcity of collagen based drug delivery systems in market is concerning, 
considering the wealth of information that exists on research-based collagen's drug 
delivery systems. In deciphering why collagen based products might not be reaching their 
full clinical potential, we reviewed the formulations of collagen used in current collagen-
based biomaterials. As such, two main categories of formulations were identified, as 
shown in Table 2. These are:  
1. Non-dissociated Fibrillar Collagen- These formulations contain decellularized 
collagen ECM particulate matter, which is mechanically homogenized, acid-
swollen, and finally lyophilized to form sponge which may or may not be cross-
linked. Such collagen formulations do not undergo polymerization since collagen 
fibers are never dissociated during this preparation method.  
2. Soluble Collagen- These are obtained from pepsin or acid solubilization of 
mammalian tissues to form viscous collagen solutions, which are then lyophilized 
to form cross-linked or non-cross-linked sponge or injectable viscous gel. They 
exhibit fluid like behavior under shear stress, and become entangled again when 
the suspension is at rest. 
Table 2: Major collagen formulations used in commercial drug delivery applications 















The major limitation of these formulations is that they do not capture and capitalize the 
inherent fibril self-assembly of collagen that occurs in vivo, and are limited by their poor 
molecular characterization. As a result, the matrices formed from such formulations lack 
interfibril branching and simply represent entanglements of long individual fibrils, that 
lead to their poor shape definition, low mechanical integrity, poor handling, cell-induced 
contraction, and rapid proteolytic degradation [4, 75-77]. To improve these properties, 
materials are subjected to exogenous cross-linking, which is achieved through chemical, 
enzymatic or physical methods [4].  
Chemical cross-linking of type I collagen matrices is typically performed using 
agents, such as glyoxal, formaldehyde, methylene diphenyl diisocyanate, hexamethylene 
diisocyanate, and most commonly glutaraldehyde [4]. Glutaraldehyde and formaldehyde 
treatment provides an advantage of cross-linking dry collagen material with reagent in 
vapor phase instead of treatment in liquid phase [9]. Although these agents achieve the 
goal of cross-linking, they also exhibit  detrimental effects on cells and tissues [78] such 
as cytotoxicity [6, 79] or tissue calcification [80-82]. For example, depolymerization of 
polymeric glutaraldehyde cross-links has been reported to releases highly cytotoxic 
glutaraldehyde and monomer fragments into the recipient [80, 83-85]. Cross-linking with 
other chemical agents, for example, diphenylphosphoryl azide, 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC)/N-hydroxysuccinimide (NHS), and oxygen 
species, were proved to be nontoxic, but the cross-linked fibers were unstable in water 
and collapsed into films in aqueous or high humidity environments [86].  Besides, cross-
linking can reduce porosity [82], limiting the nutrient transport to cells. 
Researchers have also attempted to use physical cross-linking techniques such as 
photooxidation, dehydrothermal treatments (DHT) and ultraviolet irradiation with 
photosensitizers (e.g., riboflavin) to avoid introducing potentially cytotoxic chemical 
residuals into the system and retain the biocompatibility of collagen materials [4]. 
However, most of these physical treatments cannot yield enough high cross-linking 
degree to meet mechanical strength demand of drug delivery devices [77]. Furthermore, 
collagen is reported to have been partially denatured by these physical treatments [8]. 
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Enzymatic cross-linking agents such as lysyl oxidase and tissue transglutaminase has also 
been used however limited due to feasibility issues [87]  and concerns of apoptosis [88] 
respectively.  
   Thus, while materials formed without any cross-linking are characterized as 
mechanically unstable, too soft to handle, and unable to resist cell-induced contractions, 
exogenous crosslinking  has been shown to have detrimental effects on cells and tissues 
[78], such as cytotoxicity [6, 79] or tissue calcification [80-82] and partial denaturation of 
collagen itself [86] [8].  
1.1.4 Drug incorporation method in collagen delivery systems 
While reviewing the application of collagen formulations in drug delivery 
[4],[65],[5],[66], it was realized that the methods through which drugs are entrapped 
within or attached to collagen delivery systems play an important role in determining the 
efficacy of drug delivery system. Since drug release can be influenced drastically by the 
approach taken to associate the drug with collagen matrix, it is important to understand 
the current strategies of attaching drug to collagen. An informed decision made in 
selection of strategy for drug attachment to collagen will endow us with a much better 
tool to engineer drug delivery system with improved tunability, and cell-instructive 
capacity.  
Current strategies of drug incorporation can be separated into three distinct strategies 
(Figure 6): i) physical entrapment of drug, ii) affinity binding based drug retention, and 
iii) chemical or covalent immobilization of the drug into the collagen matrix.  
Physical admixing involves direct entrapment of drug within matrix or encapsulation of 
drug, and relies on diffusion to facilitate drug release into the surrounding tissue. 
Chemical immobilization usually involves covalent binding through the use of chemical 
crosslinkers and the drug is primarily released through degradation. Affinity binding 
involves affinity based interaction between the drug and collagen substrate and drug 




Figure 4: Schematics of strategies of drug incorporation in collagen based drug 
delivery systems. 
i) Physical admixing/entrapment/adsorption of drug into collagen: Physical admixing 
involves dissolving or suspending the drug within a polymer reservoir to form a porous 
device. It is the most common strategy used for local drug delivery due to its simplicity 
and cost effectiveness [89]. Rate of drug release is controlled by diffusion dominated 
mechanisms observed initially, followed by further release as reservoir degrades by 
surface or bulk erosion [90].  Fabrication methods for entrapping drug involve 
lyophilization (freeze drying), particulate leaching, phase emulsion (microspheres) and 
in-situ polymerization (gels). Many of these methods start with slurries of shredded 
collagen or whole collagen tissue fragments that are exogenously cross-linked, and 
combined with drug at certain ratios before subjecting to lyophilization [91]. Sometimes, 
the drug is added after lyophilization as in cases of collagen sponge. During 
lyophilization, the pore-sizes that are formed within the matrices are often bigger than the 
size of the drug, resulting in diffusion dominated release. However, there is little control 
over pore size during lyophilization, which limits the ability to tune drug entrapment and 
release. Moreover, harsh condition of processing in physical entrapment method (e.g. 
homogenization used during emulsion method of formulating microspheres) can affect 
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the bioactivity of encapsulated molecules by inactivating active sites or denaturing the 
drug [92]. 
ii) Affinity based immobilization of drugs into collagen: Rather than simply admixing a 
drug in collagen, site-specific tethering of drug to the collagen gives an option of 
extending drug release by modifying the interaction between the drug and matrix. 
Affinity can be described as the tendency for one molecule to bind to another. Affinity 
based systems utilize the molecular interaction between the therapeutic agent and the 
delivery vehicle. The strength of the interaction depends on the variety of molecular 
forces: charge, hydrophobicity, hydrogen bonding, and van der Waals forces [93]. This 
non-covalent physical adsorption technique involves adsorption of drugs onto surfaces 
typically exploiting direct charge–charge or secondary drug-matrix affinity interactions, 
or indirect interaction via intermediate proteins or other biological molecules (e.g., 
heparin [94], fibronectin [95]). Such interactions have been employed to deliver basic 
fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) through 
engineered biomimetic collagen matrices, showing controlled diffusion and matrix 
degradation to induce angiogenesis [94, 96-99].  
iii) Chemical / covalent immobilization of drug on collagen: Immobilization of the drug 
within collagen matrix can also be achieved by its covalent conjugation to collagen. 
Covalent binding of drugs to collagen matrices can sustain drug release for longer time 
period and offer control over amount and spatial distribution of drug in collagen matrices. 
Drugs can be conjugated to collagen matrices via functional groups, which are 
incorporated by co-polymerization or through chemical treatment. For example, to 
overcome rapid diffusion and clearance from the implant site and to increase its 
conformational stability, recombinant transforming growth factor β2 (TGF-β2) was 
covalently bound to injectable bovine dermal fibrillar collagen (FC), using a difunctional 
polyethylene glycol (PEG) linker to create FC-PEG-TGF-β2 sequences throughout the 
matrix [100]. The activity of the covalently bound TGF-β2 was compared to admixed 
TGF-β2, and results showed that covalent binding of TGF-β2 to collagen resulted in a 
significantly larger and longer-lasting TGF-β2 response than that observed with admixed 
formulations of collagen and TGF-β2. It should be noted however, that despite 
advantages offered by this method of drug incorporation, it is difficult to selectively 
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assign specificity of the coupling site on conjugated drug as binding interactions are 
specific to each drug and difficult to predict. Also, biomolecules may lose their 
bioactivity if screening or damage of the active pockets occurs during the immobilization 
[61]. 
The ultimate success of any of the above method of drug loading, whether physical 
entrapment, affinity based retention, or covalent immobilization, is dependent on the 
preservation of collagen's native physiological properties. Physical entrapment and 
affinity based molecular retention methods are often confounded by the weak mechanical 
properties of conventional collagen formulations. As mentioned earlier, materials formed 
without any cross-linking are characterized as mechanically unstable, too soft to handle, 
and unable to resist cell-induced contractions [4, 75-77] thus failing to support cell 
ingrowth and migration required for tissue regeneration. On the other hand, exogenous 
crosslinking [4, 10, 12, 13, 86, 101, 102] or chemical immobilization based approaches 
can lead to detrimental effects on cells and tissues [78], such as cytotoxicity [6, 79] or 
tissue calcification [80-82] and partial denaturation of collagen itself [86] [8]. 
Consequently, current collagen based products suffer from problems related to 
mechanical integrity, inability to give controlled release and inflammation based tissue 
response. This limits the clinical success of collagen for tissue engineering and molecular 
delivery applications [72],[103],[104].  
1.1.5 An approach inspired by in-vivo collagen synthesis and self-assembly 
It is realized that for promoting healing of chronic wound, there is a need for design and 
development of a multifunctional collagen based platform that supports recreation of 
natural type I collagen fibril scaffold while fostering rapid and functional 
neovascularization and tissue regeneration at the site of implantation. Since the wound 
healing period can vary according to wound type, age and many other factors including 
infection, sex hormones, stress, diabetes, obesity, and medications [105], it is important 
that such a multifunctional platform supports a broad range of customizable 
spatiotemporal release profiles of biomolecules, through a loading strategy that does not 
compromise physiologically relevant properties of native collagen. As such, we decided 
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to take the inspiration from in-vivo collagen synthesis and self-assembly in the 
development of such multifunctional tissue engineering and drug delivery platform. 
In vivo, type I collagen constitutes a major structural and mechanical component of 
connective tissues and organs,  accounting for more than 90% of the ECM in skin, bone 
and tendon of vertebrates [106] and approximately 30% of total body protein [2, 4]. Its 
ability to form polymerizable, porous collagen-fibril matrix that can degrade into 
physiologically non-toxic products make it an excellent biocompatible material with low 
immunogenicity.  Additionally, its versatility and ability to be processed on an aqueous 
basis make it a viable candidate for formulating drug delivery systems [107].  Being a 
natural polymer, collagen also provides advantages related to its inherent cell-signaling 
potential which is facilitated by adhesion domains that engage in integrin-mediated cell 
binding [108]. These biophysical properties of collagen are summed up below in Figure 
5.   
 
Figure 5: Schematics showing biophysical properties of type I collagen that add to 
its advantages for forming a tissue engineering and drug delivery platform. 
The unique properties exhibited by type I collagen that are mentioned above are due to its 
complex, unique hierarchical structure [109-113]  developed during in vivo biosynthesis 
and self-assembly. The basic building block of this hierarchical structure is a collagen 
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molecule consisting of three peptide chains (two α1 (I) and one α2 (I) chain). Collagen 
molecule comprises a central helical domain flanked on each end by non-helical 
telopeptide domains [71, 114] as shown in Figure 6A.  The 300 nm-long helical domain 
consists of Gly-X-Y repeats where the X and Y positions are often occupied by proline 
and hydroxyproline.  These collagen molecules, also known as tropocollagen, are the 
fundamental building blocks of type I collagen. Tropocollagen molecules self-assemble 
in a hierarchical fashion as shown in Figure 6B, to form tissue-specific networks of fibrils 
that then combine to form suprafibrillar and tissue level structures [14].  
 
 
Figure 6: A) Schematic of type I collagen molecular structure . Figure shows three 
polypeptide chains intertwined to create a right-handed helical structure. The N- and C-
termini of the molecular structure contain the non-helical telopeptide regions. (From 
[115])  B) Hierarchical, multi-scale organization of type I collagen as it occurs in vivo 
(From[116]). 
The in-vivo biosynthesis of collagen involves ribosomal production of individual 
tropocollagen alpha (α) chains, followed by hydroxylation of specific proline and lysine 
residues which contribute to triple helix stabilization and molecular cross-linking 
respectively [14]. Processed polypeptide chains then undergo trimerization to form 
heterotrimeric procollagen molecules consisting of two α1 (I) and a single α2 (I) chains. 
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Upon extrusion into the extracellular space, both amino- and carboxy-terminal 
propeptides are cleaved enzymatically [71], thus rendering the resultant tropocollagen 
molecule capable of fibril formation [117]. As the prefibrillar aggregates of staggered 
tropocollagen molecules assemble, lysyl oxidase binds and catalyzes cross-link formation 
between prefibrillar aggregates of staggered collagen molecules (telocollagen) to create 
covalently cross-linked dimers or trimers (called oligomers) [118].  These different 
oligomer precursors direct the progressive molecular packing, fibril assembly, and 
suprafibrillar network formation that eventually gives rise to tissue-specific form and 
function [14, 119].    
1.1.6 Proposed strategy to design collagen based drug delivery platform 
Inspired by the in-vivo collagen synthesis and self-assembly, we wanted to create a 
designer collagen biograft material that would provide a strong structural support, and 
promote rapid neovascularization and tissue regeneration through tunable molecular 
release.  We decided to achieve this goal through a combination of improved collagen 
formulation, and by strategic use of physical or affinity based retention of molecules in 
collagen. The unique type I collagen building blocks we employed in the design of such 
multifunctional platform, were oligomers , and monomers such as telocollagens and 
atelocollagens  (Figure 7) that have been developed in Voytik-Harbin laboratory 
previously. These unique collagen building blocks of oligomer, telocollagen and 
atelocollagen are extracted from porcine skin type I collagen (PSC), and have been 
previously proven to predictably and reproducibly control the relevant fibril- and matrix-
level properties such as matrix pore size, permeability and diffusivity, stiffness, and cell 
surface-receptor mediated signaling [14, 120, 121]. 
 These collagen building blocks differ in their intermolecular cross-link content, 
composition and cross-link chemistries [14, 120]. While the oligomers  comprise small 
aggregates of collagen molecules (e.g., trimers), which retain collagen’s tissue-specific, 
covalent intermolecular cross-links, telocollagens  are individual collagen molecules, 
which lack these intermolecular covalent cross-links. The telocollagen and oligomer 
formulations possess intact telopeptide regions and contain reactive aldehydes building 
blocks generated from acid-labile, intermediate cross-links [14]. Upon in-vivo 
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polymerization, the process through which collagen fibrils assemble to form a gelled 
polymeric network, these reactive aldehydes spontaneously reform covalent, intermediate 
cross-links as part of the fibril-forming process. Pepsin-solubilized (telopeptide-deficient) 
atelocollagen formulations are created when collagen is treated with proteolytic enzymes 
that remove the terminal telopeptide regions. As both the amino (N)- and carboxyl (C)-
telopeptides play important roles in cross-linking and fibril formation, their complete 
removal results in an amorphous arrangement of collagen molecules and a consequent 
loss of the banded-fibril pattern in the reconstituted product  [122].  
 
 
Figure 7: Collagen polymer building blocks as defined based on cross -link type .  (A) 
Oligomer, (B) Telocollagen (C) Atelocollagen. Stars and gray bars represent reactive 
aldehydes and stable, mature covalent cross-links, respectively. 
The matrices formed from these building blocks have previously shown superior 
mechano-biological properties compared to commercially available collagen 
formulations under the same polymerization conditions [120]. The microstructural and 
mechanical properties given by these isolated unique building blocks are different from 
that obtained from collagen formulations in other categories. The relationship between 
matrix stiffness and fibril density, as exhibited by the building blocks was found to be 
important in regulating the cell behavior and vessel morphogenesis [14]. PSC showed 
decreased polymerization times, enhanced mechanical integrity and a larger dynamic 
stiffness range than the other collagen formulations [14, 120]. It then became evident that 
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fundamental differences existed between the porcine skin collagen and conventional 
collagens on the molecular level, and these are most likely due to intermolecular cross-
linking and ability of to self-assemble as demonstrated by porcine skin collagen building 
blocks [14, 120, 123]. We decided to capitalize on these inherent strengths of collagen 
building-blocks for controlling molecular release.  
This work deals with application of these unique collagen building blocks towards 
tunable molecular release through i) control of the fibril microstructure and proteolytic 
degradability of collagen at molecular level, and ii) use of affinity binding based 
approach that can prolong retention of molecules in collagen. Strategically, we employed 
heparin that has binding affinity for oligomer as well as VEGF, for loading of the 
VEGF189 molecules in oligomeric collagen, and tested its applicability towards 
enhancing neovascularization in vivo using a well-established chicken egg chorioallantoic 
membrane (CAM) assay.  
1.2 Organization of thesis  
This dissertation aims to demonstrate how specific molecular and fibril level design 
features of collagen, along with affinity binding properties, can be used to tune the 
molecular release from collagen biografts for applications such as improving local 
vascularization and tissue regeneration in engineered collagen constructs.  
In Chapter 2, we address our specific aim 1 of designing self-assembling collagen-based 
drug delivery system of low and high fibril-density, and defining how its specific 
molecular and fibril level features can modulate molecular release. We used FITC-
dextrans of various sizes ranging from 10kDa to 2000 kDa as a drug analogue in this aim. 
After matrix self-assembly and polymerization, we compared the FITC-dextran release 
from various collagen matrices in absence, and presence of collagenase. Weibull function 
was fit to the empirical data to decipher associated release mechanisms. Through this 
study, we first established use of oligomer as a robust drug delivery system compared to 
commercial telocollagen-based drug delivery system. Next, we showed how molecular 
release can be tuned by altering collagen molecular composition and fibril density. 
Lastly, we showed how varying levels of collagenase could affect molecular release from 
the low and high fibril density implants.  
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In CHAPTER 3, we addressed specific aim 3 of demonstrating application of low and 
high fibril-density collagen graft materials towards controlled VEGF delivery for 
enhancing local neovascularization in an in-vivo chorioallantoic membrane model.  To 
improve the local retention of VEGF in collagen, we exploited heparin binding affinity 
towards collagen and VEGF189. The implants were evaluated for their ability to provide 
enhanced neovascularization in an accelerated time frame of 3 days. 






























CHAPTER 2. DESIGN AND MODULATION OF COLLAGEN 
FIBRIL BIOGRAFTS FOR TUNABLE MOLECULAR RELEASE 
2.1  Introduction 
Type I collagen represents an important candidate biopolymer when considering the 
design of multifunctional tissue implants. Being a natural biomaterial, it forms major 
structural and mechanical component of the majority of connective tissues and organs in 
our body. It accounts for more than 90% of the extracellular matrix (ECM) of vertebrates 
[106] and approximately 30% of total body protein [2, 4]. Its hierarchical structure, self-
assembly and intermolecular cross-links ubiquitously preserved across species [70], and 
its ability to form porous collagen-fibril matrices with cell signaling potential make it an 
excellent material for creating multifunctional drug delivery platforms for in-vivo 
implantation.  
The hierarchical organization of collagen during its in-vivo synthesis involves binding of  
lysyl oxidase enzyme to catalyze cross-link formation between prefibrillar aggregates of 
staggered collagen molecules (monomers) to create covalently cross-linked oligomers 
(e.g., at least two collagen molecules joined by a covalent cross-link)  [14, 124, 125]. 
These different oligomer precursors (dimers or trimers) in turn, direct the progressive 
molecular packing and assembly of collagen that eventually gives rise to tissue-specific 
fibril microstructure and matrix physical properties with exceptional cell signaling 
potential, facilitated by adhesion domains that engage in integrin-mediated cell binding. 
The porous microstructure and unique biochemical composition makes collagen a viable 
candidate for drug delivery [4, 5, 65-67, 70, 71]  with most applications explored in 
ophthalmologic [126-135] dental [136], [137], wound healing  [138-140] [141] [142, 
143] [144] [145] [146], and bone regeneration [147-150] fields.   
Despite this, only a handful of collagen drug delivery systems are commercially available 
[5] [72, 151],[103],[104] [152].  Major shortcomings in conventionally available 
collagens include poor molecular characterization; low mechanical integrity and stability; 
rapid proteolytic degradation; limited design control; and deleterious tissue responses 
associated with chemical modifications [4],[9],[10, 12, 13, 86, 101, 102].  Implants 
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formed from conventional formulations are unable to form suprafibrillar structural 
assemblies as observed in vivo, instead exhibiting amorphous microstructures [72, 73] 
with low tearing strength [153],  poor mechanical integrity [154] [155], and an 
uncontrolled molecular release [72] [156] [77] [156] [157] [158] [159]. Strategies to 
overcome these limitations include utilizing exogenous cross-linking, chemical 
modification, or mixing with other natural/synthetic polymers (Appendix 2). However 
these strategies have been associated with several limitations, including but not limited to 
detrimental effects on cells and tissues [78], such as cytotoxicity [6, 79], tissue 
calcification [80-82], and partial denaturation of collagen [86] [8] or biomolecule [160].  
Here we address these shortcomings through the development of self-assembling, 
collagen-fibril biograft materials that feature integrated tissue engineering and molecular 
delivery design. More specifically, collagen polymers specified by their intermolecular 
crosslink composition and self-assembly capacity [14, 120, 121] were used to customize 
and design materials in terms of 1) collagen fibril microstructure and mechanical 
properties and 2) proteolytic degradability. While these features were found to define 
tissue formation and cell-instructive properties previously, here we exploited them to 
define local molecular release profiles. The objective of the proposed work was to 
develop a tunable, multifunctional, collagen-based platform that supports a broad range 
of customizable spatiotemporal molecular release profiles, including burst and sustained.  
The unique feature of this technology is that it capitalizes on the differential self-
assembly of collagen and avoids use of exogenous crosslinking or chemical 
modifications.  
2.2 Methods  
2.2.1 Preparation of soluble collagen formulations  
All laboratory-produced self-assembling type I collagen formulations (oligomer, 
telocollagen, and atelocollagen) were derived from the dermis of market weight pigs. 
Collagen oligomers were prepared as described previously [120]; telocollagen was 
prepared by extracting porcine dermis with 0.5 M acetic acid followed by salt 
precipitation [115, 121]; and atelocollagen was prepared via complete pepsin digestion 
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[161]. All collagens were then dialyzed exhaustively against 0.1 M acetic acid and 
lyophilized. Prior to use, lyophilized collagens were dissolved in 0.01 N hydrochloric 
acid (HCl) and rendered aseptic by overnight exposure to chloroform at 4°C. Collagen 
concentration was determined using a Sirius Red (Direct Red 80) assay [162]. 
Laboratory-produced collagens were standardized based upon purity as well as 
polymerization capacity, as described in ASTM F3089-14[163]. Polymerization capacity, 
as a functional performance criterion, is defined as the relationship between shear storage 
modulus (G’) of polymerized matrices and collagen content of the polymerization 
reaction [14, 120]. Commercial monomeric collagen, namely type I collagen acid 
solubilized from rat tails, was purchased from Corning (Catalogue Number 354249; 
Corning, NY, USA) and is referenced as rat tail collagen (RTC). All collagen solutions 
were diluted with 0.01 N HCl to achieve desired concentrations and neutralized with 10X 
phosphate buffered saline (PBS) and 0.1 N sodium hydroxide (NaOH) to achieve pH 7.4 
[120]. Neutralized solutions were kept on ice prior to induction of polymerization by 
warming to 37oC. 
2.2.2 Polymerization kinetics and capacity of oligomer collagen in absence and 
presence of FITC-dextran  
Oligomer collagen polymerization kinetics and capacity were measured in absence and 
presence of 10 kDa or 2000 kDa FITC-dextrans (Invitrogen, Eugene, OR) using an 
AR2000 rheometer (TA Instruments, New Castle, DE,) equipped with a stainless-steel 40 
mm-diameter parallel plate geometry [14, 120]. Oligomer solutions (3 mg/ml) were 
prepared in the presence and absence of relatively high concentrations of FITC-dextran (1 
mg/ml in 10X PBS), neutralized, and pipetted onto the Peltier plate. Upon lowering the 
geometry, the Peltier plate was maintained at 4 0C for 5 minutes and then increased to 
37°C for 15 minutes to induce collagen polymerization. Time-dependent changes in shear 
storage modulus (G’) were measured at 1% controlled oscillatory strain. Each matrix 
formulation was tested in triplicate (n=3). 
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2.2.3 Collagen-fibril materials containing FITC-dextran 
Collagen fibril matrices were self-assembled to entrap and deliver various sizes of FITC-
dextrans. We formulated matrices at both low fibril-density (3 mg/ml) and high fibril-
density (20 and 40 mg/ml) using the following procedures. 
2.2.3.1 Low-density collagen-fibril matrices 
Oligomer solutions (3 mg/ml) were polymerized in the presence and absence of 10 kDa, 
40 kDa, or 2000 kDa FITC-dextran (0.5 mg/ml) as described above. For some 
experiments, mixed oligomer: atelocollagen matrix formulations were prepared by 
combining neutralized oligomer (3 mg/ml) and atelocollagen (3 mg/ml) solutions at 
various ratios between 0:100 and 100:0. The neutralized collagen solutions with and 
without FITC-dextran were kept on ice prior to the induction of polymerization. Collagen 
solutions were then pipetted into 48-well tissue culture plates (Corning, NY) at 250 μL 
per well. Due to the viscosity of the collagen solutions, positive displacement pipettes 
(Microman, Gilson, Middleton, WI) were used. The collagen solutions were allowed to 
polymerize for 30 min at 37°C in a humidified incubator.  
2.2.3.2 High-density collagen-fibril matrices 
High-density oligomer matrices were created using confined compression as described 
previously [164]. Briefly, 10.4 ml and 20.8 ml neutralized collagen oligomer (4.05 
mg/ml) containing 0.25 mg/ml of 10 kDa or 2000 kDa FITC-dextran were prepared, 
pipetted into molds (2 cm width by 4 cm length), and polymerized overnight at 37°C. 
Polymerized matrices were then densified using a porous polyethylene platen (50 µm 
pore size) at 6 mm/min to final thickness of 0.26 cm, yielding matrices of 20 mg/ml and 
40 mg/ml. Disks (1.1 cm diameter) were punched from the compressed materials and 
placed in 48-well tissue culture plates for comparison with non-densified, 3 mg/ml 




2.2.4 Characterization of 3D collagen-fibril matrices 
Both low and high fibril-density collagen fibril matrices were characterized in terms of 
their microstructure and proteolytic degradability, as described below. 
2.2.4.1 Micro-structural analysis 
Collagen fibril microstructure was visualized via cryogenic scanning electron microscopy 
(cryo-SEM) using an Everhart-Thronley detector adapted to a FEI NOVA nanoSEM 200 
(FEI, Hillsboro, OR). Collagen materials were quick frozen by submersion into critical 
point liquid nitrogen, transferred to a CT1000 cold stage attachment (Oxford Instruments 
North America, Inc., Concord, MA), and sublimated under vacuum for 15 minutes before 
platinum sputter coating and imaging. Each experimental group was prepared in duplicate 
(n=2).  
2.2.4.2 Sensitivity to proteolytic degradation 
To test sensitivity of self-assembled collagen-fibril materials to collagenase degradation, 
rheologic testing was conducted. Solutions of 3 mg/ml neutralized oligomer, 
telocollagen, or atelocollagen were polymerized on the rheometer plate in adherence to 
the 40 mm-diameter parallel plate geometry for 30 minutes as described previously [14, 
120]. Polymerized collagen materials were then exposed to 1.8 ml collagenase from 
Clostridium Histolyticum (type IV, Worthington Biochemical Corporation, Lakewood, 
NJ) reconstituted at 5000 U/ml, confined in a silicone ring. Time-dependent changes in 
the tangent of phase shift delta (tan δ) were monitored in oscillatory shear using a time 
sweep conducted at 1% controlled strain. Total degradation time was defined as time 
required for inflection of tan δ to an absolute value great than or equal to 1, indicative of 
matrix to liquid phase transition. Each material formulation was tested in triplicate (n=3). 
2.2.5 Molecular Release from Collagen-fibril Matrices 
2.2.5.1 Predicting sampling interval 
Sampling time intervals for measuring molecular release kinetics from collagen materials 
were determined using an established mathematical model for monolithic matrices [165]. 
This model, based on Fick's second law of diffusion, assumes a slab matrix geometry 
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with homogeneous initial drug distribution and an associated supernatant “sink”. Short-
time equation (Eq. 1) was used for predicting first 60% of release, and long-time equation 


























Here, Mt and M∞ denote cumulative amounts of molecules released at time t and at 
infinite time respectively; D is the molecular diffusion coefficient within the system; and 
L represents matrix thickness. Matrix thickness values were 0.26 cm as defined by our 
experimental system. Diffusion coefficient values for 10 kDa, 40 kDa, and 2 MDa FITC-
dextrans were substituted as 1.09 E-10, 4.8 E-11, and 1.76 E-11 (m2/sec) respectively 
based upon published experimentally determined values for 3 mg/ml oligomer collagen 
matrices [121]. 
2.2.5.2 Measuring release kinetics 
For measurement of release kinetics, polymerized collagen-fibril matrices were exposed 
to 750 µl of either PBS (1X, pH 7.4) or collagenase from Clostridium Histolyticum (type 
IV, Worthington Biochemical Corporation) prepared at desired enzyme strength in PBS 
(1X, pH 7.4). At each sampling time, the supernatant was completely removed and 
replaced with 750 µl of fresh buffer. Supernatant fluorescence was measured using a 
spectrofluorometer (Molecular Devices Spectramax M5, Sunnyvale, CA) at excitation 
and emission wavelengths of 493 and 530 nm, respectively. This process was repeated 
until supernatant fluorescence for each well matched baseline fluorescence (PBS 
plus/minus collagenase, no FITC-dextran), indicating complete FITC-dextran release. All 
fluorescence values were normalized to maximum total fluorescence intensity and % 
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cumulative release was plotted against time. Each formulation was tested in triplicate 
(n=3). 
2.2.5.3 Quantification of release kinetics and definition of molecular release 
mechanism 
FITC-dextran release from various collagen-fibril matrices was quantified using the 
Weibull function [166] given in equation (3): 
Mt
M∞
= 1 − exp (−atb) (3) 
Here, Mt is the molecular mass released at time t, M∞ is the molecular mass released at 
infinite time (assumed equal to the amount of drug added), a denotes a scale parameter 
that describes the time dependence, and b describes the shape of the dissolution curve 
progression [167]. Here, to compensate for the sensitivity of Weibull function to minor 
deviations when Mt/M∞ % is close to 0 and 100, a weighting procedure was employed 
using (-log(1-Mt/M∞)*(1 - Mt/M∞)2 as recommended by Jacobsen [168] and 
Langenbucher [169].  Values of shape parameter b were used as an indicator of specific 
molecular release mechanisms, as suggested by Papadopoulou and co-workers [170]. 
Time required to reach 50% of cumulative release (“T50 %”) was calculated from the 
Weibull fit using Matlab (The MathWorks, Inc., Natick, MA). 
2.2.6 Statistical analysis 
The dependence of molecular release parameters as a function of FITC-dextran size and 
matrix composition was determined using ANOVA followed by a post-hoc Tukey test 
with a 95% confidence interval. A two-sample Student’s T-Test with a confidence 
interval of 95% was used to compare molecular release parameters from matrices in the 
presence and absence of collagenase. These statistical analyses were performed in 
Minitab 16.0 (Minitab Inc., State College, PA). Interaction and contour graphs for 
relationships between fibril density and collagenase level affecting T50% of release, were 
plotted in Minitab 16.0. The statistically-significant contribution of each factor, 
specifically fibril density, collagenase level, and factor interaction, was determined using 
two-way mixed model of ANOVA, through Proc MIXED procedure in Statistical 
Analysis Software (SAS Institute, Cary, NC).  
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2.3 Results  
2.3.1 Admixed FITC-dextran did not affect oligomer self-assembly capacity  
We and others have documented that collagen fibril self-assembly or fibrillogenesis is 
dependent upon a number of polymerization parameters, including buffer composition, 
pH and ionic strength, presence of copolymers (e.g., other collagen types) or accessory 
molecules (e.g., proteoglycans), collagen molecule integrity (e.g., presence or absence of 
telopeptides), as well as the presence of cells [14, 120, 162, 171-176]. Here, the effect of 
FITC-dextran molecules on oligomer self-assembly, was determined by polymerizing 
oligomer solutions (3 mg/ml) in the presence or absence of 10 kDa or 2000 kDa FITC-
dextran, each admixed at a relatively high concentration of 1 mg/ml. As shown in Table 
3, values for polymerization half time (P50%) and matrix shear storage modulus (G', Pa) 
were statistically similar for oligomer prepared with and without FITC-dextran, 
indicating no significant effect of these molecules on oligomer self-assembly capacity 
(p=.592, n=3). 








2.3.2 Prediction of diffusion-based release from oligomer collagen suggested size -
dependent release of FITC-dextran molecules  
Sampling intervals for drug release must be carefully timed to accurately capture and 
depict material-based molecular release profiles. Sampling intervals for FITC-dextran 
release from oligomer matrices were predicted using an established mathematical model 
for monolithic materials [165] and experimentally determined FITC-dextran diffusion 
coefficients[177]. As expected, the predicted time for diffusion-based release showed the 
Composition  P
50
% (min)  G’ (Pa)  
Oligomer  0.62 ± 0.03 
A
  689.93 ± 52.46
A
  
Oligomer + 10 kDa  0.57 ± 0.06 
A
  641.69 ± 52.69
A
  
Oligomer + 2000 kDa  0.62 ± 0.04 
A





tendency of larger molecules to be retained for longer times in oligomer matrices 
compared to small molecules (Figure 8). Resultant time periods were also used to 
determine supernatant collection time points for in-vitro molecular release studies.  
 
Figure 8: Small-sized molecule release is predicted to be faster than that of large 
sized molecules in 3 mg/ml collagen. Predicted size-dependent FITC-dextran release 
profiles from 3 mg/ml oligomer matrices (A) and associated T50% values (B) calculated 
using diffusion-based models as described in the Methods section. 
2.3.3 Comparison of ultrastructure and molecular release properties of collagen-fibril 
matrices formed from lab produced oligomer solution vs. commercial RTC 
solution 
 Matrices formed from conventional soluble collagen monomer formulations 
(telocollagen and atelocollagen) have three notable shortcomings, namely high lot-to-lot 
variability, poor structural integrity and high sensitivity to proteolytic degradation [164, 
178]. As such, controlled molecular release using these materials has proven challenging 
[157].  Oligomer collagen, with its uncommon molecular composition, has previously 
been shown to possess low intra-hide and inter-hide variability [120], increased 
intermolecular crosslinking [14, 121],  improved mechanical integrity [116], shape 
retention, and resistance to cell-induced contraction compared to their monomer 
counterparts   [125, 177].   
To compare the molecular release from oligomer and RTC matrices in both absence and 
presence of collagenase, 3 mg/ml oligomer and RTC collagen solutions containing 0.5 
mg/ml of 10, 40, and 2000 kDa FITC-dextrans were polymerized to form 3D matrices, 
and then exposed to 1X PBS buffer with or without 125 U/ml collagenase.  
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Visualization of self-assembled collagen-fibril ultrastructure with cryo-SEM (Figure 9A) 
showed that oligomer fibrils were more uniform in size with a greater mean diameter 
compared to RTC. These differences in microstructure and mechanical integrity between 
oligomer and RTC matrices might have contributed to the differences in proteolytic 
resistance of the two matrices, where RTC matrices showed dramatically reduced 
resistance to proteolytic degradation resulting in rapid molecular release, compared to the 
oligomer matrices.  
2.3.3.1 In absence of collagenase, oligomer matrices but not RTC matrices display 
size-dependent molecular release  
When 3 mg/ml oligomer fibril-matrices containing various sizes of FITC-dextrans were 
exposed to 1X PBS buffer without collagenase, distinct molecular size-dependent release 
profiles were obtained as shown in Figure 9B. 10 kDa FITC-dextran was retained for the 
shortest time with T50% of 11.40±1.25 hrs (mean±SD), followed by 40 kDa and 2000 
KDa with values of 15.21±1.48 hrs, and 23.44±2.95 hrs respectively. While the release of 
2000 kDa FITC-dextran was significantly slower than that of the smaller molecules 
(p=.001, n=3), there was no significant difference in release kinetics for 10kDa and 
40kDa. Release mechanisms, as determined using Weibull fits, were diffusion-based for 
all molecules tested (Figure 9B). However, 10 kDa FITC-dextran was classified as 
diffusion through a disordered substrate, while 40 kDa and 2000 kDa FITC-dextrans 
represented diffusion through a normal Euclidian substrate. These results were 
encouraging given that oligomer materials were prepared at relatively low collagen-fibril 






Figure 9: Matrices prepared with self-assembling collagen oligomers show different 
fibril ultrastructures and molecular release profiles than commercial RTC matrices .  
(A) Fibril ultrastructure of collagen-fibril matrices (3 mg/ml) prepared by polymerization 
of oligomer or RTC, as visualized by cryo-SEM. Scale bar represents 4 μm. FITC-
dextrans (10 kDa ( )́, 40 kDa (□), or 2000 kDa (●)) were admixed within 3 mg/ml 
oligomer and RTC solutions and, upon polymerization, time-dependent release from 
matrices was monitored spectrofluorometrically in absence (B) and presence (C) of 125 
U/ml collagenase. Black arrow in release profiles from RTC (C) marks complete 
degradation of matrix. Tables indicate Weibull-fit based T50% (mean±SD), parameter 
"b", and release mechanisms based on the value of “b”. Letters in T50% column indicate 
statistically different experimental groups as determined by Tukey-Kramer range test 
(n=3, p<0.05) 
In contrast, conventional RTC matrices prepared at the same collagen concentration did 
not show size-dependent molecular release (Figure 9B). T50% values ranged from 
4.14±0.21 hrs for 2000 kDa molecules to 7.10±2.18 hrs for 10 kDa and were all 
statistically similar. Moreover, the Weibull-based release mechanism, diffusion through 
disordered substrate, was the same across the molecular size range tested. When 
compared with oligomer, RTC matrices had significantly (p<0.05) lower T50% values for 
all FITC-dextran sizes.  
Thus, the molecule size-dependent release profiles and associated distinctive release 
mechanisms observed through mechanically and microstructurally integrated oligomer 
matrices, but not RTC matrices, confirmed the viability of oligomer collagen-fibril 
matrices as a drug delivery system with improved control over molecular release 
compared to a conventional collagen-based drug delivery. 
2.3.3.2 In presence of collagenase, oligomer matrices but not RTC matrices exhibit 
sustained release    
Typically, rapid proteolytic degradation-based release from conventional collagen 
materials is prevented via exogenous crosslinking or chemical modification methods [4, 
104, 159]. However, such methods have detrimental effects on cells and tissues [6, 78-
82], and on collagen itself [8, 86]. Here completely avoiding  the need for exogenous 
crosslinking or chemical modification, we attempted to control proteolytic degradation 




Molecular release was measured in presence of 125 U/ml collagenase from both 3 mg/ml 
oligomer and RTC matrices containing 0.5 mg/ml FITC-dextran (10, 40 and 2000 kDa). 
Oligomer matrices exhibited significantly greater T50% for all FITC-dextrans, compared 
to the RTC matrices (Figure 9C). Notably, oligomer matrices lasted for approximately 3 
days at the high concentration of collagenase while RTC degraded in mere 4.8 hrs, 
pointing to remarkable proteolytic resistance of oligomer matrices. 
Weibull-fits indicated that the release mechanisms through oligomer changed from 
diffusion through normal Euclidian substrate in absence of collagenase to diffusion 
through disordered substrate in presence of collagenase. However, degradation based 
release dominated RTC matrices, resulting in complex mechanism of release, where the 
rate of release initially increases nonlinearly up to the inflection point and thereafter 
decreases asymptotically [170]. This should be interpreted with caution though, since the 
rapid degradation of RTC matrices dramatically reduced the sampling availability and the 
quality of Weibull fits for RTC matrices, compared to the increased sampling and robust 
Weibull fits observed with oligomer matrices.  
Collectively, these results in presence of collagenase highlighted the ability of oligomer 
matrices to resist proteolytic degradation and exhibit significantly sustained molecular 
release, compared to the conventional RTC matrices.  
2.3.4 Matrices composed from oligomer and atelocollagen exhibit significantly 
different ultrastructure and release kinetics  
Collagen polymer precursors oligomer, telocollagen, and atelocollagen differ in their 
intermolecular crosslink composition and self-assembly capacity, giving rise to different 
fibril densities [180] and matrix physico-mechanical properties [14, 15, 120].  Since these 
parameters are known to affect  mass transport[181],  here we hypothesized that the 
molecular release kinetics can be altered by changing the collagen compositional 
precursors.  
Ultrastructural differences between matrices prepared from oligomer, telocollagen, and 
atelocollagen were visualized via cryo-SEM. While oligomer matrices displayed highly 
branched, dense, and mechanically integrated fibrillar networks, atelocollagen matrices 
were characterized with sparse, thin fibrils with minimal branching (Figure 10A). 
Telocollagen matrices showed an intermediate fibril branching and entangled fibrils.   
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Influence of different precursors (3 mg/ml oligomer, telocollagen, and atelocollagen) on 
release of   10 kDa and 2000 kDa FITC-dextran (0.5 mg/ml) was observed in both 
absence (Figure 10 B) and presence of 125 U/ml collagenase (Figure 10 C). Release 
profiles for atelocollagen differed significantly from oligomer and telocollagen (p<.001; 
n=3) For instance, the T50% exhibited by atelocollagen matrices for 10 kDa was 
0.49±0.09 hrs, significantly lower (p<0.001, n=3) than that for oligomer (11.40±1.25 hrs) 
and telocollagen (10.50±1.22 hrs) matrices. Similarly, atelocollagen exhibited 
significantly lower T50%  in case of 2000 kDa FITC-dextran compared to oligomer and 
telocollagen matrices. Oligomer and telocollagen values were however not significantly 
different. Furthermore, Weibull fitting indicated that the release mechanisms were 
different through atelocollagen matrices when compared to telocollagen and oligomer 
matrices, in both absence (Figure 10 B) and presence (Figure 10 C) of collagenase. The 
molecular release was accelerated from all matrices in presence of collagenase, 























Figure 10: Molecular release profiles of self-assembled collagen-fibril matrices are 
dependent upon collagen polymer composition.  (A) Fibril ultrastructure of collagen-
fibril matrices (3 mg/ml) prepared by polymerization of atelocollagen, telocollagen, and 
oligomer as visualized using cryo-SEM. Scale bar represents 4 μm. FITC-dextrans (10 
kDa or 2000 kDa) were admixed within 3 mg/ml atelocollagen (), telocollagen (□), and 
oligomer (●) solutions, and upon polymerization, time-dependent release was monitored 
spectrofluorometrically in absence (B) and presence (C) of 125 U/ml collagenase. 
Associated tables indicate Weibull-fit based T50% (mean±SD), parameter "b", and release 
mechanisms interpreted based on the value of “b”. Letters in T50% column indicate 
statistically different experimental groups as determined by Tukey-Kramer range test 
(n=3, p<0.05). 
 
The proteolytic degradation was observed to be different for matrices formed form 
different precursors, as  determined by exposing each of the matrices to 5000 U/ml 
collagenase on rheometer. Time sweep tracking transition of matrix from solid to liquid 
phase then indicated that the degradation time for each type of matrix was significantly 
different (p<0.001; n=3), as shown in Table 4.  Atelocollagen matrices degraded fastest, 
followed by telocollagen and then oligomer matrices. 
Collectively, these results highlighted the slowest and fastest release kinetics displayed 
by oligomer and atelocollagen precursor based matrices, identifying them as viable 
candidates for further tuning of molecular release from collagen. 
Table 4: Matrix degradation time 
Matrix Time (min)  
Oligomer 219.5 ± 10.9 
A
  
Telocollagen 186.7 ± 19.7 
B
  






2.3.5 Tuning molecular release from collagen-fibril matrices 
The structure, density, and integrity of fibrillar and nonfibrillar ECM components are 
major factors in regulation of interstitial transportation and mediation of cellular 
responses during physiological and pathological states in human body [182]. Here we 
wanted to capture these features to modulate molecular release from collagen-based 
materials. As such, we chose to systematically alter collagen fibril microstructure and 
proteolytic degradation through 1) change in compositional ratio of oligomer and 
atelocollagen precursors in the matrix, and 2) change in the polymerized oligomer fibril-
matrix density. While first strategy enabled tuning release through changes to collagen 
made before polymerization, second strategy enabled to do so after polymerization of 
collagen.  
2.3.5.1 Oligomer and atelocollagen mixed matrices enable tuning polymerization 
kinetics, ultrastructure, and molecular release kinetics  
Whittington et al. [121, 180] previously showed that by varying oligomer to telocollagen 
ratio, matrix mechanical properties as well as cell growth and differentiation can be 
guided. Park et al. further elucidated effect of modulating collagen precursor ratios on 
mass transport properties of collagen through computational modeling[181]. Here, we 
aimed at determining the effect of modulating collagen precursors, specifically 3 mg/ml 
oligomer and atelocollagen, on molecular release kinetics of both small and large sized 
FITC-dextran. Therefore, neutralized oligomer and atelocollagen solutions (3 mg/ml) 
were mixed in ratios 0:100, 25:75, 50:50, 75:25, and 100:0 respectively and its effects 
were assessed on the collagen polymerization kinetics, viscoelasticity, and molecular 
release kinetics.  
Mixing resulted in matrices with significantly different polymerization kinetics and 
stiffness (p<.05, n=3; Figure 11). Matrix stiffness and polymerization rate correlated 
positively with increase in oligomer content. All matrices except 100% atelocollagen 
polymerized within 5 minutes. Cryo-SEM was performed to determine the effect of 
mixing oligomer and atelocollagen precursors on collagen fibril ultrastructure (Figure 
12A). The 100% oligomer matrices demonstrate increased fibril thickness, density, and 
interconnectivity when compared to 100% atelocollagen matrices. Matrices containing 
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Figure 11: Collagen polymerization kinetics  are dependent upon the oligomer: 
atelocollagen ratio. Time-dependent changes in shear-storage modulus were monitored 
as collagen formulations transitioned from solution to matrix following an increase in 
temperature from 4⁰C to 37⁰C. (A) Time-dependent changes in shear storage modulation 
during polymerization were used to quantify (B) polymerization rate (mean±SD) and (C) 
polymerization half-times (P50%; mean±SD). Each sample was tested in triplicate 
 To determine the effect of mixed matrices on molecular release kinetics, 
neutralized collagen solutions (3 mg/ml) containing either 10 kDa or 2000 kDa FITC-
dextran were prepared from oligomer and atelocollagen, then mixed in ratios of 0:100, 
5:95, 10:90, 50:50, 75:25, and 100:0 respectively. Upon polymerization, matrices were 




Figure 12: Collagen-fibril matrix molecular release can be tuned by varying the 
oligomer:atelocollagen ratio.  (A) Fibril ultrastructure of collagen matrices (3 mg/ml) 
prepared by polymerization of oligomer and atelocollagen mixed at different ratios as 
visualized by cryo-SEM. Scale bar represents 4 μm. FITC-dextrans (10 kDa and 2000 
kDa) were admixed within oligomer:atelocollagen solutions prepared at 0:100 (ο), 5:95 
(), 10:90 (□), 50:50(●), 75:25(◊), and 100:0 () ratios and, upon polymerization, time-
dependent release of FITC-dextrans was monitored spectrofluorometrically in the 





In the absence of collagenase (Figure 12B), mixed matrices exhibited different release 
profiles, for both 10 kDa and 2000 kDa FITC-dextrans. Release was prolonged with 
increase in oligomer proportion in the mixed matrices. 2000 kDa FITC-dextran was 
retained for a longer time than 10 kDa FITC-dextran, indicating molecular size dependent 
release characteristic of mixed matrices. Further, the presence of collagenase highlighted 
the distinction between release profiles of various mixed matrices (Figure 12C), with a 
more pronounced effect on 2000 kDa FITC-dextran. The exaggerated differences in 
release profiles observed in the presence of collagenase might be attributed to the 
differences in proteolytic degradability associated with each collagen matrix component 
seen earlier (Table 4).  
Collectively, this method of changing collagen matrix composition through varying 
oligomer and atelocollagen ratio shed light on its effectiveness on tuning molecular 
release of both small and large sized molecules, through modulation of microstructure 
and proteolytic degradation. 
2.3.5.2 Oligomer densification tunes matrix ultrastructure and molecular release  
Previously, using the method of confined compression, Blum et al. prepared high fibril 
density oligomer matrices that possessed higher-order interfibril associations, and 
mechanical properties of soft connective tissues [116]. Due to the smaller matrix pore 
sizes [183] and increased resistance to proteolytic degradation [116] associated with these 
high fibril-density collagen matrices,  we hypothesized that confined compression can be 
used to extend drug release from collagen fibril matrices.  To test this hypothesis, 
polymerized 4.05 mg/ml oligomer matrices containing 0.25 mg/ml FITC-dextran (10 kDa 
or 2000 kDa) were subjected confined compression [164], yielding 20 and 40 mg/ml 
densified matrices. 
The effect of densification on matrix ultrastructure was revealed by cryo-SEM (Figure 
13A).  Densified matrices exhibited enhanced fibril density and higher-order interfibril 
associations, in agreement with Blum et al. [164]. 
 The effect of densification on molecular release from collagen-fibril matrices was 
determined by exposing matrices to 1X PBS buffer containing either no collagenase 
(Figure 13B) or 10 U/ml collagenase (Figure 13C). Significantly prolonged the release 
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was observed from 20 and 40 mg/ml matrices, compared to 3 mg/ml matrices (p<0.001, 
n=6). For 10 kDa FITC-dextran release, while the 40 mg/ml matrices gave a T50% value 
of 14.02±2.16 hrs, 20 mg/ml matrices closely followed with a value of 13.61±1.10 hrs. 
However, low fibril-density (3 mg/ml) matrices exhibited lowest value of 1.7±0.41 hrs. 
This distinction between molecular release properties of high fibril-density and low fibril-
density matrices was maintained for 2000 kDa FITC-dextran release as well, since the 
T50% of 20 and 40 mg/ml matrices (229.42±10.22 hrs and 339.85±3.56 hrs) were 
significantly longer than that for 3 mg/ml matrices (36.18±4.84 hrs). These higher values 
of T50% exhibited by high fibril density matrices were most striking, especially in the 
absence of any exogenous modification of collagen. Thus, 20 mg/ml and 40 mg/ml 
matrices provided a remarkable extension of 2000 kDa FITC-dextran release for up to 44 
and 55 days respectively, which is well above the release period of 
uncrosslinked/unmodified conventional collagens [4, 5, 66]. Exposure of low and high 
fibril density matrices to 10 U/ml collagenase further elucidated the role of proteolytic 
degradation in molecular release. Degradation accelerated release of 10 kDa (Figure 13C) 
as well as 2000 kDa (Figure 13D) FITC-dextran. It also amplified the distinctness of 
release profiles given by low and high fibril-density matrices. While 3 mg/ml matrices 
showed rapid release of 10 kDa FITC-dextran (T50% 1.03±0.49 hrs), 20 and 40 mg/ml 
matrices showed significantly extended (p<.001, n=6) release (T50% 8.72±1.94 hrs and 
11.98±1.70 hrs respectively). This distinctness of molecular release between low and 
high fibril density matrices was  maintained in case of 2000 kDa FITC-dextran, with 3 
mg/ml matrices showing lowest T50% (4.64±1.20 hrs), followed by 20 mg/ml 
(39.68±7.55 hrs) and 40 mg/ml (69.20±10.15 hrs) matrices. These results point to 
enhanced collagenase resistance of high fibril density matrices that must have contributed 
to the longer retention of molecules compared to that by the low fibril density matrices.    
Weibull fits showed diffusion-based release mechanisms for both 10 and 2000 kDa 
FITC-dextrans in absence of collagenase, but complex release mechanisms in presence of 
collagenase. Additionally, increased value of parameter "b" obtained for high fibril-
density (20 and 40 mg/ml) matrices reflected the decrease in disorder of the system at 
high fibril density compared to low fibril-density [170]. 
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For 10 kDa, Weibull fits indicated both diffusion- and proteolytic degradation-based 
molecular release mechanisms for 20 and 40 mg/ml matrices. The 3 mg/ml matrices 
exhibited diffusion through disordered substrate, as expected from previous results. For 
2000 kDa, 20 and 40 mg/ml matrices showed complex release mechanisms while 3 
mg/ml matrices exhibited diffusion through a disordered substrate. Release mechanisms 






















Figure 13: Increasing fibril density of oligomer matrices prolongs molecular release .  
A) Fibril ultrastructure of 3 mg/ml, 20 mg/ml and 40 mg/ml oligomer matrices as 
visualized using cryo-SEM. Scale bar represents 4 μm. Time-dependent release profiles 
of 10 kDa and 2000 kDa FITC-dextran from 3 mg/ml (), 20 mg/ml (□), and 40 mg/ml 
(●) oligomer matrices were monitored spectrofluorometrically in the absence (B) and 
presence (C) of 10 U/ml collagenase. Associated tables indicate Weibull-fit based T50% 
(mean±SD), parameter "b", and the release mechanisms interpreted based on the value of 
“b”. Letters in T50% column indicate statistically different experimental groups as 
determined by Tukey-Kramer range test (N=3, p<0.05) 
2.3.6 Oligomer fibril density modulates molecular release at various collagenase 
levels 
Tunablity in proteolytic degradation based molecular release is highly desirable in 
applications such as wound healing, where different levels of collagenase exist [184]. In 
wounds with high protease level, normal wound repair process is obstructed, and together 
with altered cytokine expressions, matrix repair and degradation rate is affected [23, 185, 
186]. In such situations, densified oligomer-fibril matrices could accelerate wound 
healing,  due to their high mechanical strength, resistance to proteolytic degradation, high 
cell signaling capacity [116], and ability to provide sustained molecular release.  On the 
other hand, faster molecular release from low fibril-density matrices may be beneficial in 
acute wounds where protease levels are low and wounds heal faster. However, even in 
each type of wound, collagenase levels are affected by the pathophysiological states, in- 
vivo locations, as well as by the age of the wound [187-189]. Therefore, it is important to 
characterize the tunability in molecular release of collagen fibril matrices under varying 
collagenase levels [190] [191]. 
To capture this scenario of varying collagenase concentrations, molecular release from 
different fibril density matrices (3 mg/ml, 20 mg/ml and 40 mg/ml) was determined in the 
absence (0 U/ml), or presence of low (10 U/ml) and high (100 U/ml) collagenase levels. 
These levels were chosen as representatives of collagenase in physiologically normal 
state, acute wound and chronic wound conditions respectively   [184, 187, 192]. This 
study was focused on molecular release of small sized FITC-dextran (10 kDa) only, since 
large molecular release is easier to control [4, 5, 193].  
Results show that an increase in fibril density of oligomer matrices affects the 
T50% values positively, while the increase in collagenase level affects these values 
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negatively (Figure 14A). An interaction exists between fibril density and collagenase 
levels (Figure 14B). Mixed ANOVA further confirmed that both the collagenase level, 
fibril density, and their interaction affected T50% significantly (p<0.001, n=6). The 
molecular release from 40 mg/ml matrices was most sustained, followed by 20 mg/ml 
and 3 mg/ml matrices at all collagenase levels (Figure 15). Contour graph of T50% plotted 
as a function of collagenase level and fibril density (Figure 14) further elucidated that 
matrix fibril density played a greater role in tuning the T50% than the collagenase level.  
These results highlight the ability of oligomer fibril matrices to modulate 
molecular release in presence of varying levels of collagenase, based on the alteration of 
their fibril density. This is a significant achievement for high fibril-density oligomer 
matrices, considering the absence of any exogenous crosslinkers or chemical modifiers 










Figure 14: Oligomer matrix molecular release is dependent upon fibril density and 
collagenase level. 10 kDa FITC-dextran was admixed within 3 mg/ml, 20 mg/ml, and 40 
mg/ml oligomer matrices and release kinetics were monitored spectrofluorometrically in 
the presence of 100 U/ml, 10 U/ml, and 0 U/ml collagenase. A) Table indicates Weibull-
fit based T50% (mean±SD), parameter "b", and related release mechanisms. Letters in 
T50% column indicate statistically different experimental groups as determined by Tukey-
Kramer range test (n=3, p<0.05). B) Interaction plot for different fibril density oligomers 
at various levels of collagenase. C) Corresponding contour plot showing the influence of 





Figure 15: Oligomer matrix molecular release is dependent upon collagenase level. 
Time-dependent release profiles for 10 kDa FITC-dextran admixed within 3 mg/ml, 20 
mg/ml, and 40 mg/ml oligomer matrices were monitored spectrofluorometrically in the 




Many complex biological tissues in the human body, including collagen-based tissues, 
display some remarkable features in common, including molecular self-assembly, 
hierarchical organization at the atomistic, molecular, and macro scales, as well as 
multifunctionality [194]. It is the microstructure and proteolytic degradability of the 
formed tissue that then plays an important role in regulating the mass transport through 
body. Therefore to control molecular transport through collagen based matrices in vitro, it 
is important to mimic collagen self-assembly, and provide control over the microstructure 
and proteolytic degradability of resultant matrices.  However, the conventional 
monomeric collagen (telocollagenic and atelocollagenic) formulations fail to capture the 
self-assembly characteristic of collagen. Unlike oligomers, these conventional 
monomeric formulations do not retain their tissue-specific, covalent intermolecular cross-
links [125]. As a result, the matrices formed from conventional collagen formulations 
display weaker mechanical integrity and rapid proteolytic degradation. Consequently, 
they fail to retain molecules/drugs for longer time and cannot be tuned to match their 
release rates to desired need.  
 To address this gap, we decided to employ a collagen polymer engineering 
approach that is inspired by the in-vivo collagen-fibril assembly. By incorporating 
collagen natural intermolecular cross-link chemistries through oligomer building blocks 
[14] we created self-assembled collagen fibril matrices that retained their multiscale 
structure and biological signaling properties. This work explores the viability of these 
self-assembled collagen fibril matrices in serving as multi-functional platforms for 
delivery of a wide range of sizes of molecules. Through systematic variation of collagen 
polymer composition and fibril density, we demonstrated the capability of these matrices 
to tune molecular release based on modulation of microstructure and proteolytic 
degradability features of matrix as the two main regulators of molecular transport. 
Notably, this tunability in molecular release under both proteolytic and non-proteolytic 
conditions, is achieved without using any exogenous crosslinking or chemical 
modification. 
In order to design and validate the potential of oligomers to formulate a multi-functional 
drug delivery system, we admixed oligomeric collagen with FITC-dextrans of sizes 10 
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kDa, 40 kDa and 2000 kDa and polymerized them to form 3D collagen-fibril matrices of 
3mg/ml density. FITC-dextrans molecule sizes were chosen to span a range of 
therapeutic molecules including growth factors, antibodies, antibacterial agents, viruses, 
nanoparticles, and plasmids[195].  
An important aspect of our experimental procedure was to emulate the in-vivo molecular 
release kinetics. Literature indicates that molecular release in vivo occurs by a 
combination of diffusion and enzymatic breakdown of the collagen matrix [196]. In 
pathological diseases such as cancer [197, 198] and chronic foot ulcers [188] well as 
during normal tissue homeostasis, [199], proteolytic degradation of collagen is caused by 
members of matrix metalloproteinase (MMP) family. To capture these in-vivo behaviors, 
we measured the release kinetics of FITC-dextran infused oligomeric matrices under two 
scenarios: 1) in absence of collagenase (diffusion only); or 2) in presence of collagenase 
(diffusion+degradation). The in-vitro model system we adopted for measuring release is a 
well-established model that has been used in the past by several researchers for 
quantifying molecular release from various collagen-based drug delivery systems[137, 
200-206]. In this model, the drug-containing collagen matrices are typically submerged in 
a small volume of PBS buffer (typically 400 to 2500 μL) with or without collagenase, the 
system is subjected to gentle shaking and the buffer volume is replaced periodically in the 
given release study period, to quantify drug elution at various time points.  In our system, 
we chose 750 μL buffer volume for submerging collagen matrices as this volume was 
within the range of previously reported buffer volumes [137, 200-206] and could fit in a 
48 well tissue-culture plate. We then  subjected the entire plate to gentle shaking 
conditions and periodically replaced buffer with fresh volume, that allowed us to quantify 
release kinetics based off of fluorescence of FITC-dextrans eluted at a given time point.  
Along with quantifying molecular release kinetics, the understanding of release 
mechanisms involved in the release process is crucial when designing a controlled release 
system[207]. For understanding and elucidating the mechanisms of drug release, 
empirical modeling of drug release has been found to play an important role [208-210].   
Characterizing molecular release from polymer matrices have been accomplished through 
use of various empirical models, including the well-known Higuchi, and Peppas and 
Weibull models [211-218].  The basic mathematical expressions used to describe the 
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release kinetics and discern the release mechanisms are elegantly described in the articles 
on Higuchi law [219] and the Peppas equation or the so-called power law ([220-222]).  
Despite their wide use,  [170, 216-218, 223], both Higuchi and power law are short time 
approximations of complex exact relationships[223, 224], therefore, their use is confined 
to the description of the first 60% of the release curve[170]. Beyond 60%, the quality of 
the fit has been observed to be poor. However, Weibull function has been found to be 
appropriate for fitting the entire set of data while effectively explaining the mechanisms 
of molecular release [170, 225-228]  and has been applied successfully by several 
researchers for discernment of drug release mechanisms [166, 226-237]. Therefore, in 
this study, Weibull function was used to fit release data, quantify T50%, and decipher the 
associated release mechanisms. 
2.4.1 Oligomeric collagen enables formation of multi-functional platforms with 
robust microstructure and extended molecular release characteristics  
To avoid the use of external agents, and yet maintain the mechanical integrity of collagen 
based drug delivery system, we used novel self-assembling oligomeric collagen building 
blocks that show a unique ability to form hierarchical fibrillar structures similar to those 
found in vivo [115, 177]. These building blocks also possess many critical design features 
amenable for engineering 3D cellular microenvironments, such as ability provide 
mechanical support as well as biological cues for cell proliferation     [14, 120, 177, 179, 
238]. A number of factors such as microstructure, matrix composition, and extent 
exogenous cross-linking can affect mass transport through collagen-based tissues and 
matrices [239-241]. Whittington et al. [177] recently showed that the inclusion of 
intermolecular cross-links as a component of the fundamental collagen building blocks 
(oligomers) affects molecular diffusion within polymerized matrices by regulating 
hierarchical assembly and interfibril branch formation. Here we extend upon that work by 
showing that oligomer collagen matrices affect the molecular release of FITC-dextrans 
differently than conventional telocollagenic (RTC) matrices, both in the absence and 
presence of collagenase. In absence of collagenase, large FITC-dextran (2000 kDa) 
release was significantly extended (p<0.05, n=3) when compared to small FITC-dextrans 
(10 kDa and 40 kDa) through oligomeric, but not RTC matrices.  Release profiles 
through oligomer matrices were distinct for both smaller and larger molecules, as 
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expected from predictive models of diffusion-based release (Figure 8). On the other hand, 
RTC matrices showed lumped release profiles (not distinguished based on sizes of FITC-
dextrans). These results demonstrate the ability of oligomeric matrices to exhibit 
molecular size-dependent release, similar to what is  observed in in-vivo tissues such as 
sclera [242] or brain ECM [243]. This is impressive because conventional collagen 
matrices have not been able to achieve such a size dependent release without exogenous 
crosslinking or modification with additives [78, 244, 245]. It is now known that cross-
linking agents such as glutaraldehyde can exhibit  detrimental effects on cells and tissues 
[78] and non-collagenous additives affect the physiological properties of matrices. 
In simultaneous experiments with collagenase (125 U/ml), ability of oligomer fibril 
matrices to give sustained release (Figure 9C) was highlighted, in contrast to the rapid 
release displayed by RTC matrices that were completely degraded in just 4.8 hrs. 
However, at the same high collagenase level, the oligomer matrices persisted for about 3 
days, highlighting their enhanced resistance to proteolytic degradation.  Notably, this 
resistance is observed in absence of any exogenous crosslinking, while it is typical to use 
exogenous crosslinkers in conventional collagen formulations for obtaining sustained 
molecular release in presence of collagenase[192, 246, 247].  
The molecular release differences observed between oligomer and RTC matrices could 
be attributed to their ultrastructure differences (Figure 9A). Cryo-SEM comparison of 3 
mg/ml oligomer matrices with conventional telocollagenic RTC matrices revealed that 
oligomer matrices had a uniform, interconnected porous nature when compared to the 
non-uniform fibril ultrastructure and weak mechanical stability of conventional RTC 
matrices. Oligomer matrices also exhibited superior handling properties compared to 
RTC matrices during the cryo-SEM sample preparation, as the RTC matrices were 
observed to be physically breaking apart during the loading of samples on SEM sample 
stage, while the oligomer matrices remained intact.  The low mechanical integrity of RTC 
matrices has been observed previously [120] and could be due to the poor mechanical 
stiffness  of telocollagenic formulations [238, 248] that the RTC matrices are claimed to 
be made of [249]. Previous reports have shown that oligomer matrices were significantly 
stiffer than their telocollagenic counterparts when polymerized at the same collagen 
concentration, owing to increased interfibril branching [177] [238, 248]. Thus, the altered 
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packing and alignment of collagen molecules that occurs in the presence of covalently 
cross-linked molecules (oligomers) during self-assembly may have resulted in increased 
interfibril branching and distinct hierarchical architecture [120]. 
The release mechanisms that were inferred from Weibull fit-based parameters indicated 
differences in release from oligomer and RTC matrices in both absence and presence of 
collagenase. In the absence of collagenase, release from oligomeric matrices emulated 
diffusion through normal Euclidian substrate while that through RTC matrices was 
similar to diffusion through a disordered substrate (Figure 9). Similar differences were 
observed in presence of collagenase as well, with oligomer showing diffusion through 
disordered substrate, but RTC matrices showing complex release mechanism. However, 
the mechanisms in RTC case had to be interpreted carefully, due to the poor Weibull fit 
(R2) values observed. These could be attributed to the rapid degradation of RTC matrices 
causing reduction in sampling availability and thereby affecting the Weibull fitting of the 
data [250].  
In general, RTC matrices exhibited significantly faster diffusion compared to that shown 
by oligomer matrices. Such a rapid release from conventional non-crosslinked collagens 
has been previously observed. For example, basic fibroblast growth factor (bFGF) was 
released from non-crosslinked collagen matrices during the first 6 hours [251]. Similarly, 
a collagen sponge incubated with rhBMP-2 (~26 kDa) solution released 55% of the 
protein in 1 h and 100% in 2 days [252].Larger molecule Riboflavin (376.36 g/mol) was 
also released in a short duration of 16 hours from collagen sponges [253].  Implantation 
of a gentamicin-impregnated collagen sponge Garamycin in horses resulted in peak 
concentration of gentamicin within 3 hours [254]. Considering these burst release 
examples from conventional collagen, the ability of oligomeric collagen to provide both 
size-dependent and sustained molecular release in both the absence and presence of 
collagenase appears impressive. These results indicate the potential of these unique 
building blocks in forming a multifunctional drug delivery platform capable of delivering 
a wide range of molecules without the need for exogenous agents. 
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2.4.2 Tuning microstructure and molecular release properties of oligomer fibril 
matrices 
The ability to provide sustained drug release is not adequate for the success of a drug 
delivery implant in vivo. Implants should be tunable in terms of their mechanical, 
microstructural, and molecular release properties to match tissue regeneration rates, as 
these rates can vary based on the location of soft tissue damage or  its healing stage,  as 
well differences in an individual’s age, dietary intake, healing rate, and lifestyle-related 
factors [255]. Despite wide research and promising results of collagen-based materials in 
improving therapeutic efficacy and delivery [3, 4, 66], the inability of the collagen based 
systems to provide tunable release is still a major limitation restricting its clinical utility. 
Challenges in tuning molecular release from conventional collagen matrices stem from 
open weave structure of collagen [4]. This problem is compounded by the poor 
characterization of conventional formulations in terms of their molecular composition 
and inability to fully capitalize on the inherent self-assembly or polymerization capacity 
of collagen leading to weak mechanical integrity and cursory control over physical and 
molecular release properties [14, 15, 116, 248]. Hence, to tune molecular release from 
collagen, it has been necessary to rely on methods such as exogenous crosslinking, 
mixing with another polymer phase, covalent or non-covalent bonding, or sequestration 
in a secondary matrix as listed in Table 1. However, such steps not only increase the 
complexity of the system, but also alternative microstructure of collagen [256, 257]. 
Therefore, a combination of improved collagen formulation and a tuning strategy that 
does not alter physiologically relevant properties of collagen is desirable to improve 
tunable molecular delivery from collagen.  
Here, we addressed this problem with the use of self-assembling oligomer building 
blocks that have been shown to retain physiologically relevant crosslinks [14]  and have 
been used to predictably and reproducibly control fibril- and matrix-level physical 
properties for the creation of 3D in-vitro tissue systems [116, 125] while illustrating 
robust physico-mechanical properties [14, 120, 177, 179, 238].  To tune molecular 
release using these novel oligomer building blocks, we applied two strategies that can 
preserve the physiologically relevant microstructure of collagen: 1) modulating the 
polymer composition through change in compositional building blocks of collagen; and 
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2) densifying oligomer fibril matrices. While the first strategy offers an option of tuning 
matrix microstructure, degradation, and release properties before polymerization of 
collagen, the second strategy offers this tunability after polymerization.  
2.4.3 Tunability by altering polymer composition   
It has been known that modulation of collagen microstructure and composition affects 
molecular transport from collagen-based materials [239-241, 258-260]. Literature survey 
also reveals that collagen precursors (atelocollagen, telocollagen and oligomer) show 
differences in mechanical [116, 120], physical [14], and biological properties  owing to 
the different interfibril branching capacity of the precursors. Here we wanted to extend 
upon this work by studying the effect of these precursors on molecular release from 
collagen. First, we observed microstructural differences between oligomer, telocollagen 
and atelocollagen (Figure 10A), that could be attributed to the interfibril branching 
differences observed between these precursors previously. For example, Kreger et al. 
[120] observed slight decrease in fibril density of atelocollagen based PureCol matrices at 
0.5 and 2 mg/ml concentrations, and Whittington et al. observed increased interfibril 
branches in oligomer when compared to telocollagen (also called monomer) at 1.5 mg/ml 
collagen concentration [115]. When effect of this changing microstructure between 
oligomer, telocollagen and atelocollagen was studied on molecular release kinetics, 
oligomer matrices were found to provide the slowest release kinetics in contrast to  the 
fastest release kinetics provided by atelocollagen matrices, under both absence and 
presence of collagenase conditions (Figure 10B and C respectively). These differences in 
molecular release can be attributed to the differences in proteolytic degradation (Table 4) 
as well as differences in ultrastructure between oligomer and atelocollagen fibril 
matrices. Telocollagen showed release characteristics slightly faster than oligomer, but 
they were not statistically significant. As a result, oligomer and atelocollagen precursors 
displaying slowest and fastest release kinetics were identified as viable candidates for 
further tuning of molecular release from collagen. 
Upon further mixing of oligomer and atelocollagen in different ratios, both matrix 
microstructure and molecular release were found to be affected (Figure 12). Increases in 
oligomer percentage was correlated with improved fibril thickness and fibril inter-
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connectedness (Figure 12A). Furthermore, increase in oligomer percentage within the 
mixed matrices led to an increase in matrix stiffness, an increase in polymerization rate, 
and a decrease in polymerization half time (Figure 11) that is in agreement with previous 
reports  that studied effect of increasing oligomer content in mixed matrices consisting of 
oligomer and telocollagen [123]. These effects can be attributed to an increase in 
interfibril branching [179].  
Molecular release was also modulated through the mixing of oligomer and atelocollagen 
in different ratios (Figure 12 B and C). In absence of collagenase, variations in release 
profiles for both small and large FITC-dextran were obtained - ranging from burst to 
sustained -  by increasing the oligomer percentage within mixed matrices (Figure 12B). 
This tunability, especially for small molecule 10 kDa, cannot be achieved with the use of 
conventional collagen formulations in the absence of secondary retention mechanisms 
[72],[103, 193]. The presence of collagenase further exaggerated this tunability, 
especially for large molecules (2000 kDa FITC-dextran). This was most likely due to the 
differences in proteolytic degradation of oligomer and atelocollagenic matrices that 
contributed to existing differences in diffusional release. In general, molecular release of 
2000 kDa FITC-dextran was slower than that of 10 kDa FITC-dextran, which is in 
agreement with previous reports documenting increased diffusional hindrance for large 
molecules when compared to small sized molecule [193, 261]. Collectively, these results 
demonstrate effectiveness of mixing oligomer and atelocollagen precursors in tuning 
molecular release as well as matrix degradation.  
2.4.4 Tunability via densification of oligomer fibril matrices  
 Increasing fibril density or collagen concentration is another way to controls 
molecular release as this approach decreases matrix porosity [4, 5]. This strategy has 
been previously applied to control release of a number of molecules from collagen-based 
materials. For example, by varying collagen content from 1.5% to 2.0% and 2.5 %,  
FITC-coupled pexiganan release from collagen was extended from 24 h to 48 h and 72 h 
respectively [262]. Lauzon et al. observed that modulating the concentration of collagen 
hydrogels from 1.5 to 4.5 mg/ml affected pBMP-9 interaction with collagen and its 
molecular release [263]. Fujioka et al. [73, 264, 265]observed sustained release of various 
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proteins by increasing collagen density using methods such as ethanol immersion and air 
drying. While these methods were successful in tuning molecular release, an associated 
concern is decrease in the porosity to an extent that  cell migration and proliferation can 
be hampered [4].  Therefore, it is important to maintain a balance between matrix 
porosity and collagen concentration.   
Another problem associated with densifying collagen matrices is the viscosity of 
collagen. Practically, due to the high viscosity, formulating collagen solutions at 
concentrations above 10% has been very difficult [70, 73, 174].  Therefore, alternative 
methods such as reverse dialysis[266], continuous injection and evaporation [267] and 
centrifugation followed by polymerization [268] have been attempted to increase the 
density of collagen. Unfortunately, these methods can require weeks to months to prepare 
and can result in matrices with varying microstructures[116], and limited cell migration 
or infiltration into the densified material [269, 270].  
 To overcome these limitations, and to better approximate the structural hierarchy 
and mechanical properties of mature tissues, Blum et al. recently used the method of 
confined compression on oligomeric collagen matrices to yield high fibril density 
matrices with high cell viability [116]. Due to the success of this technique in 
maintaining collagen microstructure and physiological relevance (D banding pattern) 
even at high fibril density, we decided to apply it for molecular release. As such, high 
density oligomer fibril matrices (20 and 40 mg/ml) containing either 10 or 2000 kDa 
FITC-dextran were formulated from low fibril density matrices (3 mg/ml) through 
irreversible removal of the interstitial fluid component in a confined format.  
The resultant matrices showed an increase in fibril density (Figure 13A) and mechanical 
integrity, in agreement with previous reports, where increasing collagen concentration 
has been correlated with increase in fibril density and a concomitant increase in matrix 
stiffness [14, 116, 120, 271, 272]. Oligomers, as distinct collagen building blocks form 
more elastic and stiffer fibrillar and suprafibrillar assemblies by fostering formation of  
interfibril branches [116] [14] compared to conventional collagens. Since these factors 
are known to affect molecular transport from collagen, we hypothesized that molecular 
release can be affected through the use of densified oligomer matrices.  
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 Indeed the densification of matrices from 3 mg/ml to 20 mg/ml and 40 mg/ml 
significantly extended molecular release profiles and increased retention of both 10 kDa 
and 2000 kDa FITC-dextrans (Figure 13B & C). In absence of collagenase, release 
through both low and high fibril density matrices was found to be diffusion-based, as 
indicated by Weibull-fit based parameters. When matrix density was increased from 3 
mg/ml to 20 mg/ml, both 10 kDa and 2000 kDa FITC-dextran release was significantly 
prolonged. However, upon increase of fibril density from 20 to 40 mg/ml, only 2000 kDa 
FITC-dextran release was further extended, thus elucidating that both fibril density and 
molecular size influenced release kinetics.   
 Further exposure of the collagen matrices to 10 U/ml collagenase amplified the 
molecular release differences between low and high fibril density matrices. This 
exaggeration in molecular release differences can be a result of differences in proteolytic 
degradation of matrices. Such differences in the proteolytic degradation of low and high 
fibril density oligomer matrices were previously observed by Blum et al. [116]. In line 
with these results, slowest degradation based molecular release was observed from 40 
mg/ml matrices, followed by that through 20 mg/ml and 3 mg/ml matrices. Thus, as fibril 
density of matrices was decreased, the degradation based molecular release was 
enhanced.  Collectively, these results show that by varying the fibril density of oligomer 
matrices, we could provide a broad range of tunability for both small and large sized 
molecular release, both in the absence and presence of collagenase.   
2.4.5 Tuning proteolytic degradation based molecular release  
Conventional collagen implants with minimal or no crosslinking degrade so quickly that 
the scaffolds disappear before the host tissue can deposit its own ECM [273]. Therefore, 
there is a need to control degradation of implants [274] as well as their degradation-based 
molecular release kinetics. However, collagenase levels vary in normal versus 
pathophysiological states and also at various locations in vivo [187, 188]. Moreover, the 
level of collagenase varies according to age of the wound [189]. Therefore, it is important 
for collagen-based implants to be tunable in terms of their molecular release under 
varying collagenase levels[190] [191].  
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 While many studies have documented controlled degradation of collagen-based 
materials [275, 276] and drug delivery devices [277-279], these were conducted at only 
one level of collagenase. Literature about collagen-based drug delivery devices providing 
controlled degradation at varying collagenase levels [187, 277] is sparse. Moreover, data 
for enzymatic activity is limited. Therefore, to choose appropriate levels of collagenase in 
demonstrating tunable proteolytic degradation based molecular release, we reviewed 
literature describing in-vivo concentrations of collagenase [184] [192] [187] and selected 
collagenase levels of  100 U/ml and 10 U/ml as representative values of matrix 
metalloproteinase equivalents present in chronic and acute wounds. The collagenase at 
the levels of 100 U/ml and 10 U/ml was then used to compare molecular release in their 
presence to that in absence of collagenase (Figure 14). From Figure 14A and C, it can be 
observed that the low collagenase level and higher fibril density provided maximum 
molecular retention. This can be attributed to a proportionate decrease in enzymatic 
breakdown of collagen with decreasing collagenase concentration [192] and enhanced 
resistance to proteolytic degradation with increased fibril density [116]. Furthermore, the 
interaction plot Figure 14B showed that collagenase level, fibril density as well as the 
interaction of collagenase and fibril density with each other had a significant effect on 
molecular release. To find out which of the two factors- collagenase level or fibril density 
had a more dominant effect on tuning molecular release, we plotted a contour graph 
(Figure 14C) where the changing gradient of contour colors from light grey to dark grey 
indicated increasing T50% values. The color change was fastest on x axis (fibril density) 
than on y axis (collagenase level), indicating the dominant role of fibril density parameter 
in affecting T50% values, compared to role of collagenase level. Amongst all fibril 
density matrices, 40 mg/ml matrices exhibited the greatest resistance to collagenase and 
therefore displayed the most extended release (Figure 15).  
Weibull function-based modeling showed the effect of fibril density and collagenase 
level on the release mechanisms. Interestingly, 40 mg/ml matrices showed different 
release mechanisms at each collagenase level (Figure 14A), i.e. diffusion with 0 U/ml 
collagenase, diffusion+degradation in presence of 10 U/ml, and first order release in 
presence of 100 U/ml. These results offer key information about the behavior of different 
matrix fibril densities in response to different proteolytic levels, conveying the potential 
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of oligomeric collagen in providing proteolytic resistance and control over diffusional 
release, even in the presence of high levels of collagenase.  
2.5 Conclusion 
There is a significant challenge in the design and manufacture of multifunctional biograft 
materials from conventional collagen due to their poor mechanical properties, rapid 
proteolytic degradation, and cursory control over physical properties and molecular 
release profiles.  
This work attempts to address these limitations by the application of novel self-
assembling collagen-fibril biograft materials. More specifically, collagen polymers 
specified by their intermolecular crosslink composition and self-assembly capacity were 
used to customize and design materials in terms of 1) collagen fibril microstructure and 
mechanical properties, and 2) proteolytic degradability, collectively defining overall local 
molecular release profiles. Results showed that by altering collagen fibril-level features 
that dictate matrix-level microstructure and degradation properties, collagen-based 
platforms were successfully formed for tunable delivery of both small and large sized 
molecules. 
 
With its uniform, highly branched and porous microstructure, coupled with its high 
mechanical integrity and high tunability, we believe the self-assembling collagen-based 
matrices have a clear advantage over conventional collagens, increasing their potential to 





CHAPTER 3. APPLICATION OF COLLAGEN FIBRIL 
BIOGRAFTS FOR ENHANCING LOCAL VASCULARIZATION 
IN AN IN-VIVO CHICK CHORIOALLONTOIC MEMBRANE 
(CAM) MODEL 
3.1 Introduction 
As a result of their difficult-to-heal nature, complex and chronic wounds, such as skin 
ulcers, are increasingly impacting the health and life-style of our society and remain a 
major clinical challenge. At present, 6.5 million people are affected by chronic wounds in 
the United Stated alone [17] with an estimated 25 billion dollars spent annually to treat 
these patients. This societal and economic burden continues to escalate largely owing  to 
increasing health care costs, an aging population, and a higher incidence of diabetes and 
obesity [19].  
Chronic wounds fail to heal because of an imbalance between extracellular matrix (ECM) 
deposition and degradation, impaired cell recruitment, and lack of essential 
neovascularization [28]. Normal healing of acute wounds represents a multi-step process 
beginning with hemostasis and inflammation during the acute stages of healing, followed 
by phases of robust cellular proliferation, ECM deposition, matrix remodeling, and 
ultimately scar formation [17, 24]. However, in chronic wounds, the dynamic spatio-
temporal interaction between endothelial cells, angiogenesis factors, and surrounding 
ECM proteins is impaired [280], causing the wound to be in a permanent inflammatory 
state [16] and display increased proteolytic activity contributed by excessive production 
of matrix metalloproteinases (MMPs) [25, 26]. MMPs in turn break down components of 
the ECM and inhibit growth factors that are essential for tissue synthesis and regeneration 
[27]. Therefore, promoting recreation of the natural type I collagen fibril scaffold while 
fostering rapid and functional neovascularization and tissue regeneration at wound site, is 
pivotal to restoration of healing of chronic wounds.   
As such, many efforts have been lately focused on the design and development of 
collagen based biomaterials that can provide the structural and mechanical support for the 
cellular infiltration and growth, while promoting the neovascularization at the wound site. 
A number of advanced wound dressings, and skin substitutes have been introduced in the 
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wound care market during the last decades [32, 34-39, 281]. However, no general 
satisfactory clinical solution has been achieved to date [32, 282] because of undesirable 
outcomes of these products, including inflammation mediated healing leading to scar 
formation rather than tissue regeneration, slow neovascularization and cellularization and 
a need for multiple applications that adds to patient discomfort, pain and healthcare cost. 
Therefore, there is an acute need to overcome these problems through improved design of 
multifunctional collagen biografts. 
An alternative of combining growth factors into collagen could potentially address the 
issue of slow vascularization and tissue regeneration through collagen based products, 
[59-61], since growth factors play important regulatory role in  tissue repair and 
regeneration in wounds (e.g. granulocyte-macrophage colony stimulating factor (GM-
CSF), platelet derived growth factor (PDGF), vascular endothelial growth factor (VEGF), 
and basic fibroblast growth factor (bFGF)) [283]. Among the various growth factors, 
VEGF is one of the most potent proangiogenic growth factors that significantly impacts 
wound vascularization  [284]. VEGF is a 45 kDa heterodimeric heparin-binding protein, 
acting as a potent mitogen (ED~50: 2-10 PM) for micro and macrovascular endothelial 
cells derived from arteries, veins and lymphatics, inducing their proliferation, migration 
and tube formation [285]. VEGF level rises in normal wound repair, leading to a vigorous 
angiogenic response, however, in chronic, nonhealing wounds, active VEGF falls to 
abnormally low level, due to possible degradation of VEGF by the excessively high 
protease activity in chronic wounds [286]. Poor vascularization which is a hallmark on 
chronic wounds such as diabetic foot ulcers, can therefore benefit by the use of VEGF 
delivery [287].  
Lately, the important role of ECM in coordinating VEGF signaling in wounds in-vivo has 
come to light [61, 92]. ECM localizes VEGF via heparin and heparan sulphate 
proteoglycan (HSPG) molecules [282, 288]. Heparin or HSPGs have highly negative 
charge (approximately 75) due to the prevalence of sulfate and carboxylate groups, that 
endows heparin with an ability to electrostatically bind to many basic biomolecules, 
including proteins, growth factors, proteases and chemokines [289]. The binding of 
VEGF to heparin occurs through such electrostatic interaction (affinity binding) [290].  
Heparin then facilitates binding of VEGF to its two receptors Flt-1/VEGFR1 and Flk-
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1/VEGFR2 through binding and stable complex formation with neuropilin (NRP)-1 
coreceptor, resulting in phosphorylation and further signaling activity of VEGF [291], 
such as providing essential stimulatory cues to initiate vascular branching [292] as well 
as endothelial tip cell filopodia emission [293]. Heparin binding thus regulates the 
physiological effect of VEGF on endothelial cells [294-296]. Heparin plays another 
important role of enabling the ECM to act storage depot of growth factors. Because of 
affinity of heparin for type I collagen in ECM, heparin retains VEGF in ECM, protects it 
from proteolytic degradation [297-300], and allows prolonged presentation of VEGF to 
cells [301, 302].  
Inspired by this role of ECM, heparin and VEGF in providing coordinated biochemical 
and biomechanical cues for in vivo vascularization, and due to well documented affinity 
of heparin for VEGF and ECM [303-306], many systems have incorporated heparin 
based interactions in collagen for loading of VEGF [64, 98, 307-311] previously. 
However, these systems consisted of monomeric collagen formulations that were 
chemically crosslinked for retention of heparin. As a result of chemical crosslinking, 
VEGF had to be loaded in the last step of formulation, so that chemicals used for 
croslsinking would not destroy the bioactivity of VEGF. VEGF was then loaded typically 
either through immersion of the formulated matrices into VEGF solution or through 
impregnation of VEGF in the matrices, both of which can lead to low VEGF loading 
efficiency. Furthermore, VEGF used in these formulations is VEGF 165 that binds to 
heparin through  positively charged lysine and arginine residues encoded by exon 7 of 
VEGF gene [312]. However, it is also known that VEGF 189 isoform contains in addition 
to the amino acids encoded by exon 7,  24 amino-acids that are derived from exon 6, 
constituting yet another heparin binding domain [313]. As  a result, VEGF 189 shows 
stronger affinity for heparin due to presence of two heparin binding domains [314, 315] 
and these binding sites  are reported to be distinct from VEGF's receptor-binding domain 
[316].  
Considering the stronger affinity of VEGF189 for heparin, and binding affinity of 
heparin for type I collagen self-assembling molecules, we decided to engineer a unique 
self-assembling collagen based biograft system that can act as a storage depot for 
VEGF189 and promote vascularization of the implant in an accelerated manner (Figure 
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16).  A key element of our design approach is the application of type I collagen 
oligomers, which represent a soluble collagen formulation capable of self-assembling 
into collagen-fibril matrices with higher-order interfibril associations. As such, the 
supramolecular assembly of oligomers supports the creation of collagen–fibril matrices 
with a broad range of structural and mechanical properties (specified by fibril density and 
matrix stiffness) beyond those that can be achieved with conventional collagen 
monomers, such as atelocollagen, and telocollagen [14, 120, 121]. Heparin was added to 
oligomer molecules in selective quantities that did not alter the oligomer molecule self-
assembly and viscoelastic properties and VEGF189 was added in quantity lower than 
heparin. Through single step admixing, the collagen containing heparin and VEGF 189 
was self-assembled.  This process relied on simple affinity based retention of heparin and 
VEGF  in the polymerized collagen system, without the use of any exogenous chemical 
crosslinking, which is in stark contrast to current approaches that rely on chemical 
crosslinking based immobilization of heparin or VEGF in the collagen scaffolds [64, 98, 
251, 310, 317, 318]. 
 Thus, the design of collagen implants in our study differs from previous systems in the 
following aspects: 1) Application of oligomeric collagen as opposed to monomeric 
collagen formulations; 2) Use of lower quantities of heparin that do not alter collagen 
polymerization properties; 3) Use of VEGF189 instead of VEGF165 due to its stronger 
heparin binding affinity; and 4) pure affinity-based retention of heparin in collagen as 
opposed to chemical immobilization. 
We hypothesized in this study, that through affinity based binding of heparin and VEGF 
in self-assembling oligomer implants, the vascularization as well as cellularization 
potential of collagen scaffolds can be improved for tissue engineering and tissue 
regeneration applications. To test this hypothesis, we designed low and high fibril density 
oligomer implants with and without heparin and VEGF molecules, and evaluated their 
functionality in enhancing local vascularization using an established in-vivo 




Figure 16: Graphical representation of design strategy used in this study. Affinity of 
heparin for collagen and VEGF189 was exploited to retain VEGF in self-assembled 
oligomer matrices. Chicken egg chorioallantoic membrane (CAM) assay was used to test 




3.2.1 Preparation of soluble collagen formulations  
Oligomeric self-assembling type I collagen was derived from market weight pig 
dermis, as described previously [120]. Extracted collagen was lyophilized for storage and 
dissolved in 0.01 N hydrochloric acid (HCl) for use. Oligomer collagen solution was 
rendered aseptic by exposure to chloroform overnight at 4°C and was standardized based 
upon purity as well as polymerization potential, as described in ASTM 3089-14 [163]. 
Here, polymerization potential is defined as the relationship between the shear storage 
modulus (G’) of the polymerized matrices and the collagen content of the polymerization 
reaction [14, 120]. The oligomer collagen solution was diluted with 0.01 N HCl to 
achieve desired concentrations and neutralized with 10X phosphate buffered saline (PBS) 
and 0.1 N sodium hydroxide (NaOH) to achieve pH 7.4 [120]. Neutralized solutions were 
kept on ice prior to induction of polymerization by warming to 37oC. 
3.2.2  Polymerization kinetics and viscoelastic properties of collagen 
Oligomer collagen polymerization kinetics and viscoelastic properties were measured in 
the presence of 0, 0.5, 1, 5, 10 or 100 μg/ml heparin sodium salt (H3149, Sigma Aldrich, 
St. Louis, MO, USA), using an AR2000 rheometer (TA Instruments, New Castle, DE) 
equipped with stainless-steel 40 mm-diameter parallel plate geometry [14, 120]. 
Oligomer solutions (3 mg/ml) with or without heparin were neutralized and pipetted onto 
the Peltier plate. Upon lowering the geometry, the Peltier plate temperature was 
maintained at 4o C for 5 minutes and then increased to 37o C for 15 minutes to induce 
oligomer polymerization. Time-dependent changes in shear storage modulus (G’) were 
measured at 1% controlled oscillatory strain. Each matrix formulation was tested five 
times (N=5). 
3.2.3  Formation of heparinized oligomer implants with and without VEGF 
3.2.3.1 Low fibril-density implants 
 In total, 4 implant groups were prepared with 3 mg/ml oligomer collagen, namely 
i) Coll (Oligomer collagen alone); ii) Coll + VEGF (Oligomer collagen + 0.5 μg/ml 
VEGF189); iii) Coll + Hep (Oligomer collagen + 1 μg/ml Heparin); iv) Coll + Hep + 
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VEGF (Oligomer collagen + 1 μg/ml Heparin + 0.5 μg/ml VEGF189). Heparin and/or 
recombinant human VEGF 189 (Abcam, Cambridge, MA) were solubilized in 10X PBS 
in desired quantities and admixed with oligomer.  Solutions were then pipetted into 48-
well tissue culture plates (Corning, Corning, NY) at 0.25 ml per well, followed by 
induction of polymerization by warming at 37oC overnight. In some instances, implants 
were washed in sterile 1X PBS by gentle rotation on microplate shaker (ThermoFisher 
Scientific, Waltham, MA) for 24 hrs. All references of admixing VEGF 189 in this work 
are henceforward referred to as simply "VEGF" addition. 
3.2.3.2 High fibril-density implants 
 High-density oligomer implants were created using confined compression as 
described previously [116]. Briefly, neutralized oligomer of concentration 4.56 mg/ml 
(with or without 1 μg/ml heparin and 0.5 μg/ml VEGF) was prepared on ice, and pipetted 
into 48-well tissue culture plate at 1.1 ml per well. The plate was incubated overnight at 
37oC to induce polymerization of oligomer. Polymerized matrices were then densified 4.4 
X, using a porous polyethylene platen (50 µm pore size) at 6 mm/min to final thickness 
of 0.26 cm, yielding 0.25 cm3 densified collagen implants at 20 mg/ml concentration. 
Based on the addition of heparin and VEGF, the resultant 20 mg/ml, high-density 
implants were classified into 4 groups, similar to those in low-density implants. Washing 
of select implants was conducted as described for low-density implants. 
3.2.4 Characterization  
3.2.4.1 Assessing spatial distribution and retention of heparin in oligomer 
 To visualize heparin localization within matrices, fluorescein conjugated heparin 
(FITC-heparin, H7482, Fisher Scientific, Carlsbad, CA) was dissolved in 10X PBS and 
used to neutralize 3 mg/ml oligomer collagen. FITC-heparin containing oligomer 
solutions were then pipetted on Lab-Tek chambered cover glass slides (Nunc, Thermo 
Fisher Scientific, Rochester, NY) and polymerized overnight in a 37oC incubator. 
Samples were washed for 24 h with 1X PBS and compared with unwashed samples for 
FITC-heparin retention.  Confocal microscopy was performed on implants using an 
Olympus Fluoview FV1000 confocal system adapted to an Olympus IX81 inverted 
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microscope (Olympus, Tokyo, Japan). Image Z-stacks (10 µm depth; 0.5 µm step size) 
from at least three random locations within each matrix were taken with a 60X  water 
immersion objective at 4X digital zoom using 488 nm excitation and 510-530 emission. 
3.2.4.2 Quantifying heparin retention in collagen 
 The amount of heparin in collagen implants was quantified using the 1,9- 
dimethylmethylene blue (DMMB) assay [319]  adapted for microplate reading [320]. 
Heparinized oligomer constructs were prepared as described above. All 3 mg/ml washed 
and unwashed collagen implants were digested with an equal volume (250 μL)  of a 
digestion buffer consisting of 1 mg/ml papain, 6.9 µg/ml of sodium phosphate 
monobasic, 0.326 µg/ml of N-acetyl cysteine, and 0.76 µg/ml of EDTA tetrasodium salt 
(Sigma-Aldrich, St. Louis, MO) dissolved in H2O. Digestion was performed at 65°C for 
24 hrs. DMMB dye was added to papain-digested samples and absorbance measured at 
525nm and 595nm wavelengths using a spectrophotometer (Molecular Devices 
Spectramax M5, Sunnyvale, CA). Sample heparin concentrations were then determined 
from a standard curve generated with known heparin concentrations [321]. All standard 
solutions and samples were prepared in triplicate and assayed three times (N=3, n=3).    
3.2.5 Chicken chorioallantoic membrane (CAM) vascularization assay 
 The CAM assay was performed as described elsewhere [322, 323]. Briefly, 
fertilized White Leghorn chicken eggs (Poultry Unit, Purdue University Animal Science 
Research Center) were horizontally positioned and incubated at 38 o C under 58% + 2% 
relative humidity in an egg incubator equipped with a turner which automatically rotated 
the eggs 5 times/day until day 7 [324]. On day 8, a window of approximately 2.5 cm 
diameter was created using a Dremel tool (Dremel, Racine, WI) equipped with a cutting 
disc.  The window was sealed with adhesive tape and eggs were returned to the incubator. 
On day 9, collagen implants were inserted on the CAM of viable eggs. The implant 
groups consisted of i) CAM alone; ii) CAM with washed 10 mm diameter paper disc 
(Sigma-Aldrich, St. Louis, MO); iii) Absorbable collagen dressing Helicote (Integra Life 
Sciences, Plainsbboro, NJ) - referred to in this work as Integra collagen; and iv) 3 mg/ml 
oligomer. CAM was digitally photographed on day 9 and day 12 after completion of the 
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assay. In another set of experiment, washed low density (3 mg/ml) and high density (20 
mg/ml) implants (Coll; Coll + VEGF; Coll + Hep; and Coll + Hep + VEGF) were 
inserted on CAM to determine effect of heparin and VEGF189 infused oligomer implants 
on vascularization. Post 3 days of implantation, on embryonic day 12, all  CAM samples 
were photographed and fixed in situ using 4% paraformaldehyde as per to protocol [325].  
Each experimental group was assigned at least 6 viable eggs (N=6-8). The timeline of 
CAM assay is shown in Figure 17. 
 
Figure 17: The schematics of CAM assay timeline  (A). The pictorial visualization of 
assay steps between embryonic day (ED) 9 and 12 is shown in part B. Image 1 in part B 
shows a window cut open in egg on ED8, image 2 shows implantation of 3 mg/ml 
oligomer implant on ED9, and image 3 shows the status of implant on ED12. 
3.2.6 Scoring vascular response and contraction of implants used in CAM assay 
The vascularization response was determined using two scoring schemes to compare 
photographs from day 12 to those from day 9. A “vascular score” was determined by 
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scoring the vessel density and distribution (5 = strong, 1 = weak) around the collagen 
implants on CAM [326], by observing top view as shown in Figure 18. Similarly, vessel 
tortuosity and abnormality in CAM was scored on a scale of 1 to 5 (5= 
irregular/tortuous/brush like, 1 = normal), based on observation of irregular vessels or 
fine brush-like vessels on CAM. Percent contraction of implant area (mm2) was also 
quantified based on the differences between implant area observed on day of insertion 
(day 9) and day of CAM harvest (day 12 or 18).  
 
Figure 18: Implant evaluation for vascular response.  (A) Implants were evaluated for 
their vascularization ability by scoring CAM vessel response from top view, before 
performing histological staining. (B) Drawings representing examples of different 
vascular responses in CAM assay. A ranking method from 1-5 was used for semi-





The fixed, excised CAM tissue samples were analyzed with the help of Purdue Histology 
Research Lab. Samples were routinely processed, sectioned and stained for Hematoxylin 
and Eosin. All samples were sectioned at 5um thickness using a rotary microtome. Slides 
were imaged with a Nikon Eclipse E200 optical microscope using 40, and 4X objective 
to visualize CAM cells and capillaries invading the implants. 
3.2.8 Statistical Analysis  
The differences between all experimental groups were determined using ANOVA 
followed by a post-hoc Tukey test with a 95% confidence interval, except for identifying 
difference between heparin content in washed versus unwashed matrices. For that 
purpose, a two-sample Student’s T-Test with a confidence interval of 95% was used. For 
all tests, p<0.05 was considered significant. All the groups were analyzed using Minitab 
16.0 statistical software (Minitab Inc., State College, PA). 
3.3 Results 
3.3.1 Upto 1 µg/ml heparin does not affect oligomer polymerization kinetics and 
viscoelastic properties 
Previous studies have shown that heparin affects self-assembly or polymerization of 
conventional monomer formulations (telocollagen and atelocollagen),  altering matrix 
consistency and viscoelastic properties [327]. Here we determined the effect of heparin 
on oligomer collagen polymerization and viscoelastic properties and defined heparin 
levels that do not alter matrix physico-mechanical properties. Based on the oscillatory 
shear based tracking of rate of change of the storage modulus (G') of oligomer containing 
different amounts of heparin (Figure 19A), we found that the polymerization kinetics of 3 
mg/ml oligomer was statistically similar for heparin concentrations up to 10 μg/ml 
(Figure 19B). At 100 µg/ml a significant decrease in polymerization half time was 
observed (Figure 19B). Evaluation of heparin addition on matrix viscoelastic properties 
(Figure 19B) showed that addition of 0.5 and 1 μg/ml had no significant effect; however,  
addition of heparin at 5, 10, and 100 μg/ml resulted in a significant lower G' (p<0.05, 
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N=5). Collectively, these results confirmed that addition of upto 1 μg/ml heparin does not 
alter oligomer polymerization and viscoelastic properties.  
 
Figure 19: Effect of heparin on oligomer matrix polymerization kinetics and 
viscoelastic properties .  (A) Time-dependent changes in shear-storage modulus of 3 
mg/ml oligomer with 0, 0.5, 1, 5, 10 and 100 μg/ml of heparin. At t=0, temperature was 
raised to 37°C to induce matrix self-assembly. (B) Polymerization half-times represented 
by P50% (mean±SD), and shear storage modulus (G’, Pa) after 15 minutes of 
polymerization (mean±SD), were quantified from the curves in (A). Each sample was 
tested five times (N=5). Letters in P50% and G' column in (B) indicate statistically 
different experimental groups as determined by Tukey-Kramer range test (N=5, p<0.05). 
3.3.2 Heparin colocalizes with oligomer fibrils and is retained after washing 
Heparin is known to bind to type I collagen monomer formulations with high affinity 
[328-330] and its effect on collagen fibril size and self-assembly has been studied 
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extensively in the past [327, 330-333]. Here, heparin localization and retention within 
self-assembled oligomer matrices was measured using confocal microscopy and 
established DMMB assay.  
 
Figure 20: Heparin in oligomer matrix is retained after washing. The amount of 
heparin retention was confirmed by 1, 9- dimethylmethylene blue (DMMB) assay (A). 
Asterisk (*) indicates significant difference based on two sample student's T test (N=3, 
n=3, p<0.05). Fluorescein conjugated heparin (FITC-heparin,) was loaded in oligomer 
matrices at 100 μg/ml concentration to visualize heparin localization within matrices. 
Image Z-stacks (10 µm depth; 0.5 µm step size) were taken with a 60X water immersion 
objective at 4X digital zoom using 488 nm excitation and 510-530 emission. FITC-
Heparin was observed to be colocalizing in oligomer fibril matrix (3 mg/ml) (B) and was 
found to be retained in matrix after 24 h washing (C). Scale bar in (B) and (C) represents 
10 μM.   
DMMB results indicated that  the concentration of heparin detected in unwashed 
oligomer matrices with 0.5, 1, 5, 10 and  100 μg /ml heparin was 0.33, 1.19, 4.97, 11.84, 
117.61 μg /ml respectively, and that in washed matrices was 0.29, 0.31, 1.17, 2.72, 24.74 
μg /ml  respectively (Figure 20, A). The increased amount of heparin retention with 
increased heparin addition in oligomer matrices is in agreement with previous studies 
[327, 332]. It was evident that while the washing step eliminated superficially attached 
heparin at all concentrations (except for 0.5 μg /ml), at least 21% or higher amount of 
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heparin was retained in all matrices. The exact percentage of heparin retained in washed 
oligomer matrices containing 0.5, 1, 5, 10 and 100 μg /ml was 88.75%, 25.75%, 23.60%, 
22.96%, and 21.03% respectively. 
Corroborating results obtained using confocal imaging suggested that retained heparin 
was associated and co-localized with formed collagen fibrils. (Figure 20, B and C).  
3.3.3 Oligomer implants but not Integra collagen or paper disc exhibit enhanced 
vascularization response in CAM after 3 days of implantation 
To determine the capability of oligomer implants in inducing vascularization in vivo, we 
implanted non-heparinized 3 mg/ml oligomer implants in CAM model between 
embryonic day 9 and 12 and compared its evoked vascular response on CAM with that of 
the CAM inserted without any sample, or with samples of paper disc, and commercial 
Integra collagen sponge.  
The visual appearance of these implants in their hydrated state before implanting on 
CAM is shown in Figure 21. The paper disc, and the 3 mg/ml oligomer implants (Figure 
21, A and C respectively) were observed to maintain shape integrity upon hydration, 
however,   however, the Integra collagen implants (Figure 21B) could be easily deformed 
into any shape upon hydration.  
 
Figure 21: Visual appearance of implants used in testing vascular response in CAM 
assay. Samples include A) Paper disc B) Integra collagen C) 3 mg/ml (low-density) 
oligomer. Scale bar represents 5 mm length. 
After implantation of oligomer, paper discs and Integra collagen samples for 3 days on 
CAM, the blood vessel density and distribution of CAM surrounding the implants was 
77 
 
scored using a semi-quantitative ranking system [326], as indicated in Figure 18 B. CAM 
without any inserted sample served as a control (Figure 22, A). It was observed that 
compared to the vascular response induced on CAM by the paper disc (Figure 22, B) or 
the Integra collagen sponge (Figure 22, C), 3 mg/ml oligomer implants showed enhanced 
vascular response to the implant (Figure 22, D).  Among all the implant groups tested, the 
3 mg/ml oligomer implants ranked significantly higher in their vascular score (p<0.05, 
N=6). The Integra collagen showed no significant difference in their vascular score 
compared to paper disc (Figure 22 E).  
 
Figure 22: 3 mg/ml oligomer implants promoted enhanced vascular response of the 
CAM around constructs compared to paper disc and Integra collagen samples . 
CAM was implanted with various test sample groups represented by (A) No sample, (B) 
paper disc, and (C) Integra collagen and (D) 3 mg/ml oligomer implant. Images were 
taken with digital camera and represent top view of implants in situ. Scale bar= 5 mm. 
(E) Vascular score calculated from top view images. Letters represent statistically 
different groups determined by Tukey-Kramer range test (N=6-8, p<0.05). H&E staining 
was performed on transverse histological sections of CAM implanted with F) no sample 
G) paper disc H) Integra collagen I) 3 mg/ml oligomer. Black arrows in G) and H) 
indicate empty spaces observed within the samples. Cells from CAM were found to 




Interestingly, both Integra collagen and oligomer implants contracted significantly 
compared to the paper disc samples by day 3 of implantation. We suspected that this 
contraction in part could have been contributed by cell infiltration as suggested by 
Kilarski et al. [334]. To determine whether Integra and oligomer collagen samples indeed 
supported cell infiltration, we performed histology on transverse sections of the CAM 
implanted with Integra and oligomer collagen samples, after their in situ fixation. 
Results of the H&E staining of transverse histological cross-sections of implants on CAM 
are shown in Figure 22 (F-I). Both the oligomer (Figure 22I) and Integra collagen (Figure 
22H) were observed to be infiltrated by cells from the CAM. However, the Integra 
collagen showed highly porous structure indicated by black arrows in Figure 22H. Paper 
disc also showed large empty spaces, however CAM cells failed to invade them (Figure 
22G). These results also showed that the oligomer matrices were in close contact with the 
CAM tissue, pointing tissue integrity, as opposed to the non-intact and highly porous 
paper disc and Integra collagen samples on CAM tissue. Collectively, these results 
showed that oligomer implants enhanced vascular response of CAM around the 
constructs while maintaining cell infiltration within the constructs. 
3.3.4 CAM vascular response around the implants is affected by contents and 
density of oligomer fibril implants  
After observing that 3 mg/ml oligomer alone induced a vascular response on CAM, we 
decided to test if the functionality of oligomer implants in inducing vascularization on 
CAM can be further enhanced through incorporation of heparin and VEGF. Heparin and 
VEGF incorporation was also performed in high fibril density implants,  since high fibril 
density implants have been shown to add tunability and scalability in design of self-
assembled collagen constructs, recapitulating the multi-scale structural and  functional 
properties of soft tissues in vivo [116]. 
Therefore, we prepared 4 groups from both low fibril density and high fibril density 
matrices for implantation on CAM, namely - i) Coll group, ii) Coll + VEGF group, iii) 
Coll + Hep group, and iv) Coll + Hep + VEGF group. All groups were washed with 1X 
PBS for 24 h in order to remove any unbound heparin and VEGF from oligomer matrix. 
Our hypothesis was that the heparinized oligomer implants would retain VEGF longer 
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due to affinity of VEGF for heparin, and as a result, induce more robust vascularization in 
vivo. 
 After 3 days of implantation, results showed that densified 20 mg/ml constructs occupied 
larger area on CAM (Figure 24 A-D) compared to the low fibril density 3 mg/ml implants 
(Figure 23A-D), indicating the successful resistance to contraction as quantified in Table 
5. Both low and high fibril density oligomer implants containing heparin and VEGF 
together (Coll + Hep + VEGF group)  exhibited a strong vascular response in the form of 
a spoke wheel pattern (Figure 23 D and Figure 24 D), which can be attributed to the 
successful retention of VEGF in the implant. Oligomer implants with heparin alone (Coll 
+ Hep group) showed a weaker vascularization response (Figure 23 C and Figure 24 C), 
with thinner vessels drawn towards the construct. The oligomer alone (Coll group) 
showed only slight vascular response (Figure 23 A and Figure 24 A), while oligomer with 
VEGF (Coll + VEGF) showed vascular response which was found to be abnormal due to 
tortuous, fine-brush like or irregular appearance of the vessels (Figure 23 B and Figure 24 
B).  
Semi-quantitative scoring of CAM vascular response indicated that heparinized oligomer 
implants induced higher vascularization than non-heparinized implants, in both the cases 
of 3 and 20 mg/ml oligomer (Figure 23 E and Figure 24 E). Addition of VEGF to 
heparinized oligomer implants further enhanced the vascularization capacity in 3 mg/ml 
implants, but addition of VEGF to non-heparinized implants triggered an abnormal 
vascular response showing tortuous and/or fine brush-like vessel formation, resulting in 
high tortuosity score in both low and high fibril density oligomer implants (Figure 23 F 
and Figure 24 F). This result highlighted the effectiveness of heparin in retaining VEGF 
within the oligomer implant, leading to enhanced vascular response on CAM, as opposed 






Figure 23: Heparinization improved vascular response of CAM to low fibril-density 
oligomer implants . (A-D) Top view of implants imaged in situ using digital camera. 
CAM was implanted with 3 mg/ml collagen consisting of oligomer alone (A), oligomer + 
0.5 µg/ml VEGF (B), oligomer + 1 µg/ml heparin (C), and oligomer + 1 µg/ml heparin + 
0.5 µg/ml VEGF (D). Tortuous vessels were observed in VEGF loaded implants without 
heparin (B), while VEGF-loaded implants with heparin showed a clear spoke-wheel 
pattern of vascular response (D). Vascular score (E) and tortuosity score (F) calculated 
from top view of implants. Scale bar represents 5 mm. Letters represent statistically 




Figure 24: Heparinization of high fibril-density oligomer implants improved 
vascular response of CAM while preventing abnormal vessel formation.   CAM was 
implanted with 20 mg/ml collagen consisting of oligomer alone (A), oligomer + 0.5 
µg/ml VEGF (B), oligomer + 1 µg/ml heparin (C), and oligomer + 1 µg/ml heparin + 0.5 
µg/ml VEGF (D). (A-D) top view of implants imaged in situ using digital camera. VEGF 
loaded implants without heparin (B) induced tortuous vessel response, while VEGF 
loaded implants with heparin induced normal and enhanced local neovascularization (D). 
Scale bar= 5 mm. (E) Vascular and (F) tortuosity score calculated from top view. Letters 
represent statistically different groups determined by Tukey-Kramer range test (N=6-8, 
p<0.05). 
The abnormal vascular response on CAM could have been likely a result of free, passive 
diffusion of VEGF out of the oligomer. To confirm this speculation, we implanted 3 
mg/ml oligomer implants containing VEGF alone (Coll + VEGF) on CAM immediately 
after overnight polymerization without involving any washing step, and expected to see a 
heightened tortuous response on CAM after 3 days of implantation. Results of this study 
showed an increased chaotic, tortuous and fine brush like vessel response on CAM 
(Figure 25 A). Further to confirm that this response was due to free diffusion of VEGF 
alone was and that oligomer in conjunction with VEGF was not causing the abnormality, 
we applied a paper disc soaked in VEGF on top of CAM, and post 3 day implantation, 





Figure 25: Uncontrolled release of VEGF results in tortuous / abnormal vascular 
response on CAM. Black arrows indicate tortuous vessels while blue arrows indicate 
fine brush like vessels and abnormality. Scale bar represents 5 mm 
3.3.5 Collagen implant composition and fibril density modulate cell infiltration 
and capillary formation within the implants 
The evaluation of CAM vasculature from top view of the various low (Figure 23) and 
high (Figure 24) fibril density implants informed us about the vascularization induced by 
the implants around, but not within the constructs. Therefore, to evaluate the vascular 
ingrowth within the low and high fibril density implants, we applied standard histological 
analysis (H&E staining of tissue slices) capturing the cellular interaction between CAM 
and the implant at their interface.  
Results showed that both 3 mg/ml (Figure 26 A) and 20 mg/ml (Figure 26 E) oligomer 
fibril implants supported some cell infiltration from CAM, however, the ingrowing cells 
did not appear to be organized or aligned in a particular direction. The addition of VEGF 
alone in oligomer implants did not seem to increase cell infiltration in low fibril density 
(Figure 26 C) or high fibril density (Figure 26 G) implants, although it seemed to have 
promoted higher vascularization on the surface of the CAM. In contrast, addition of 
heparin alone to the oligomer resulted in enhanced cell infiltration with invading cells 
aligned perpendicular to the CAM (Figure 26 B- low fibril density implants, and Figure 
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26 F - high fibril density implants). Finally, the implants containing both heparin and 
VEGF exhibited a dramatic increase in the cell infiltration while maintaining cell 
alignment (Figure 26 D - low fibril density implants and Figure 26 H - high fibril density 
implants). This group also showed remodeling of the collagen and most importantly, 
exhibited functional capillary formation inside the implants.  The functionality of the 
capillaries inside both the 3 mg/ml (Figure 26 D) and 20 mg/ml (Figure 26 H) implants 
was evident from the nucleated red blood cells found inside the lumens of these 
capillaries. The 20 mg/ml Coll + Hep + VEGF implants showed higher cell infiltration 
and cell alignment into the collagen implant compared to the 3 mg/ml implant (Figure 26 
H versus  Figure 26 D), which could be on account of higher VEGF retention due to 
increased fibril density. Collectively these histology-based results indicated that the 
response of CAM vasculature both around and inside the implants was dependent on 
presence of heparin and VEGF, as well as the fibril density of implants. 
3.3.6 Summary of implant contraction, cellular infiltration and capillary 
formation    
Table 5 summarizes the contraction, cellular infiltration and capillary formation results 
for all collagen implants tested in this study. Interestingly, the 20 mg/ml oligomer 
collagen implants showed the least contraction, and it was not significantly different from 
the contraction showed by Integra collagen.  Integra implants showed cell infiltration but 
not capillary formation. In general, the 20 mg/ml oligomer implants showed improved 
mechanical integrity and resistance to contraction, compared to the 3 mg/ml oligomer 
implants.   
Cellularization and capillary formation was highest in the Coll+Hep+VEGF group of 
both the 3 and 30 mg/ml 20 implants. The Coll + Hep group showed the second highest 
cellular infiltration and capillary formation in both 3 and 20 mg/ml implant groups. The 
cellular infiltration shown by Coll and Coll +VEGF group was lowest. It was evident that 
the heparinized implants with VEGF promoted higher cellular infiltration inside implants 




Figure 26: Response of CAM cell invasion and vascularization varies according to 
contents and density of oligomer implants . H&E staining of histological transverse 
section of CAM implanted with 3 mg/ml (A-D) and 20 mg/ml (E-H) oligomer implants.  
Samples consisted of oligomer alone (A&E), oligomer + 1 µg/ml heparin (B&F), 
oligomer + 0.5 µg/ml VEGF (C&G), and oligomer + 1 µg/ml heparin + 0.5 µg/ml VEGF 
(D&H). Heparinized VEGF-containing implants (D&H) promoted highest cellular 
infiltration and capillary formation inside the implants while non-heparinized VEGF-
containing implants promoted capillary formation on CAM outside the implant periphery 
(C&G). Black arrows indicate capillary formation. Scale bar represents 50 μM.  
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Table 5: Comparison of contraction, cellular infiltration and capillary formation 






Mean ± Std. 
Dev.  
% Contraction 











    
1. Integra  39.06 ± 13.75 
A
  50.27 ± 17.51
 D
  ++ -  
3 mg/ml Implants  
    
1. Oligomer  15.78 ± 5.73 
C
  83.39 ± 6.03
 A
  +  -  
2. Oligomer + 
Heparin  
18.08 ± 8.08 
BC
  80.97 ± 8.50
 AB
  +++  +  
3. Oligomer + 
VEGF189  
20.35 ± 5.38 
BC
  78.59 ± 5.66
 ABC
  ++  -  
4. Oligomer + 
Heparin + 
VEGF189  
15.91 ± 7.19 
C
  83.26 ± 7.56 
AB
  ++++  +++  
5. Oligomer + 
VEGF189 
(unwashed)  
19.30 ± 5.52 
BC
  72.56 ± 12.64
 ABC
  +  -  
20 mg/ml Implants  
    
1. Oligomer  45.38 ± 9.42 
A
  52.24 ± 9.91 
D
  +  -  




  59.31 ± 10.15
 CD
  +++  +  
3. Oligomer + 
VEGF189  
43.80 ± 10.79 
A
  53.91 ± 11.35
 D
  ++  -  
4. Oligomer + 
Heparin + 
VEGF189 
32.31 ± 8.71 
AB
  66.00 ± 9.16
 BCD




This study makes a contribution to the field of research aimed at enhancing and 
accelerating the vascularization capabilities of collagen based biomaterials, for potential 
use as engineered substitutes of tissues grafts. Inspired by the physiological role of 
heparin in securing binding of VEGF to the ECM, we created self-assembled oligomer 
matrices infused with heparin and VEGF that showed enhanced vascularization potential. 
While heparin effects on collagen properties and vascularization has been studied in the 
past [64, 98, 307-311], these studies involved heparin addition in conventional 
monomers, not oligomers. Here, we report the use of oligomers for heparin based VEGF 
retention in collagen implants, and evaluate their functionality for promoting 
vascularization in vivo through a well-established CAM assay. Heparin and VEGF 
incorporation in the implants was enabled through a single admixing step, and heparin 
amount was chosen such that it did not alter physiological self-assembly of oligomer. 
Furthermore, to enhance the mechanical strength and VEGF retention within the 
implants, we increased the fibril density of the implants and determined its efficacy in 
promoting microvasculature both around and within the implants. Both low and high 
fibril density collagen materials maintained their inherent self-assembly, resulting in 
preservation of native mechanical integrity and biological signaling properties of 
collagen. Due to the ability of these implants in enhancing local neovascularization and 
cellularization in an accelerated manner, these implants offer potential use as an ideal 
platform for integrated tissue engineering and molecular therapy design.  
For improving the vascularization ability of collagen scaffolds through VEGF 
incorporation, a variety of approaches have been adopted in the past, including simple 
physical entrapment, adsorption, and covalent immobilization as indicated in Table 6, and 
through affinity based retention approaches shown in Table 7.  However, simple physical 
entrapment  (Table 6, approach A) or adsorption (Table 6, approach B) of VEGF in 
collagen  can be  ineffective due to its rapid outward diffusion and quick loss of 
bioactivity [192]. More serious problems such as abnormal, tortuous and leaky vessel 
formation on account of the uncontrolled release of VEGF  can lead to clinical failure of 
constructs[296]. Therefore, to prevent uncontrolled release of VEGF, covalent 
immobilization of VEGF has been developed (Table 6, approach C). While chemical 
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immobilization was able to prevent passive diffusion of VEGF, it comes with a 
disadvantage that chemical cross-linkers alter the inherent biological signaling capacity 
of collagen and can result in adverse tissue responses [8, 77].  Moreover, it also presents 
a danger of damaging the functional group or the screening of active pocket of the VEGF. 
Table 6: Selective strategies used for VEGF delivery from collagen based delivery 
systems 
































Legend used in above schematics: 
 
 
To surpass these limitations, heparin affinity based retention of VEGF in collagen 
implants has emerged as an attractive option recently (Table 7). However, for heparin 
incorporation, number of studies (Table 7, A-D) have used chemical crosslinker called 
EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) and  NHS  (N-
hydroxysuccinimide)    that activates heparin for immobilization in collagen [64, 98, 307-
311]. While this cross-linking also serves to improve the mechanical strength and 
proteolytic resistance of conventional collagen formulations, it alters the native 
physiological structure of collagen due to chemical cross linkage [345].  As a result, 
fibrillar mechanics is also affected, and since cell traction forces and adhesive behavior 
depends on these fibril mechanics, any alteration to this native structure of collagen also 
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affects cell proliferation and movement [330]. Furthermore, due to EDC/NHS chemical 
crosslinking step, VEGF has to be loaded to the matrices in a last step, through 
immersion or impregnation, resulting in low loading efficiency. Moreover, it is currently 
not possible using EDC chemistry to independently vary implant stiffness vs. the amount 
of immobilized VEGF [342]. Finally, the heparin quantities used for VEGF retention are 
also high, and effect of heparin on collagen fibril mechanics is not always given,  
although it is now known that heparin can alter both microstructure and mechanical 
properties of collagen [327, 330, 332, 346-348].  
We addressed these issues though a design strategy purely relying on affinity based 
retention of heparin and VEGF as opposed to using exogenous chemical crosslinkers. 
Exploiting heparin affinity for collagen and VEGF, we created heparin and VEGF 
infused oligomeric collagen implants (Table 7, Strategy E) that retained their 
physiologically relevant self-assembly properties as will be seen in following section. 
3.4.1 Selecting heparin quantity that does not affect oligomer matrix self-assembly 
In vivo, heparin based VEGF retention has been found to increase endothelial cell 
proliferation, upregulate microvasculature formation, and stimulate blood vessel 
maturation [64, 96, 349, 350]. However, in-vitro addition of heparin has illustrated that 
these effects are concentration dependent and beneficial effects were found only at low 
concentrations (0.1-1 μg/ml) of heparin [290, 351], while higher concentrations (10-1000 
μg/ml) of heparin progressively inhibited the VEGF binding  [291, 352]. These results 
prompted us to carefully select heparin concentration for admixing to oligomer, so as to 
obtain beneficial effects of VEGF binding.  
Another important consideration in selecting heparin concentration for addition to 
oligomer was its effect on collagen fibril self-assembly. Heparin is known to bind to type 
I collagen fibrils with high affinity (Kd= 150 nM) [329]. However, several investigators 
over the past few decades have reported that the presence of heparin during collagen 
fibrillogenesis in vitro could have a profound concentration dependent effects on fibril 
size, interconnectivity, diameter, and organization [327, 330, 332, 346-348], that could 
impact cell growth [332]. Stamov et al. recently reported that these gross physiochemical 
and morphology changes could be attributed to competitive binding of  telopeptides and 
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heparin to similar regions along the triple-helical main region of intact tropocollagen, 
leading to inhibition of formation of asymmetric D-staggered fibrils [330]. 
Table 7: Selective strategies used for VEGF delivery from heparinized collagen 
materials 














































Heparin bears the highest density of negatively charged groups among all other 
GAGs [358] which can trigger the electrostatic interaction with other macroionic 
molecules [359]. Heparin–type I collagen interactions likely rely on the basic triple-
helical domain present at amino acid positions 87–94 near the N terminus of type I 
collagen monomer, and at multiple sites within native fibrils [328, 329]. Weak heparin 
binding sites were also observed near the carboxy terminal region of monomeric 
tropocollagen between positions 755 and 933 [328, 360]. The regions containing 
elements of NH2 terminus with affinity for heparin were highly basic, and found near the 
interface between the overlap and gap region of collagen. However, these regions are also 
known to be participating in the cross-link formations of collagen [328]. As telopeptides 
and heparin are prone to bind to similar regions along the triple-helical main region, it has 
been proposed that heparin binding at this position competitively inhibits the formation of 
asymmetric D-staggered fibrils [330].  
It was noted however, that the profound effects of heparin on the processes of fibril 
formation, growth and higher-level organizations of collagen matrices were found to be 
concentration dependent [327, 330, 332, 346-348]. While low concentrations of heparin 
were reported to be promoting fibril formation, high concentrations inhibited fibril 
assembly [327, 332, 333, 347].  However, the concentration range of heparin, ratio of 
collagen and heparin, as well as the investigation techniques varied considerably in these 
studies, making it difficult to paint a consistent picture of the important parameters of 
heparin interaction with collagen.  Moreover, these studies with heparin were carried out 
on monomeric collagen formulations, not oligomer formulations. Therefore, before 
employing the strategy of heparin based VEGF retention in oligomeric collagen, it was 
extremely important to find the effect of heparin on oligomeric collagen polymerization 
and viscoelastic properties.   
We assessed this effect by adding heparin to 3 mg/ml oligomer solutions in concentration 
range of 0 to 100 μg/ml through a simple admixing step, allowing electrostatic interaction 
based binding of heparin to the oligomer molecule, and then assessed the effect of 
heparin on matrix polymerization kinetics, viscoelastic properties and final stiffness of 
polymerized oligomer matrices (Figure 19). Results of this study indicated that upto 1 
μg/ml addition of heparin to oligomer collagen did not alter its mechanical stiffness, 
91 
 
visco-elastic properties or polymerization kinetics. However, at higher concentrations (5, 
10 and 100 μg/ml), the viscoelastic properties and stiffness of matrix decreased 
significantly. These findings are consistent with previous findings where addition of 
heparin in pepsin-solubilized bovine dermal collagen resulted in formation of a less 
cohesive matrix [162, 327, 332].  
While it is known that heparin and collagen form stable complexes due to electrostatic 
interactions between the highly anionic heparin and the positively charged groups of 
collagen [361, 362], the possibility that not all the added heparin binds to oligomer - was 
taken into consideration. Some heparin could be merely physically entrapped in 
polymerizing matrix. Since this free (unbound) heparin in collagen matrix could result in 
its uncontrolled diffusion out of collagen, it was thought to eliminate any unbound 
heparin from the collagen matrix using large excess of 1X PBS for 24 h. To quantify the 
remaining heparin in washed matrices, we performed DMMB assay, exploiting the fact 
that heparin forms colored complexes with the cationic dye 1, 9-dimethylmethylene blue. 
All samples were papain digested before the assay to make entire amount of heparin 
present in matrix  accessible for the dye complexation [363].  
The DMMB assay confirmed successful elimination of unbound heparin from oligomer 
matrices, as the quantity of heparin in washed matrices was significantly lower than 
unwashed matrices at all concentrations tested from 1 to 100 μg/ml (Figure 20 A). At 1 
μg/ml heparin addition in oligomer, we found that approximately 26% of added heparin 
was retained in the washed matrices. Further, confocal microscopy based visualization of 
FITC-heparin in oligomer matrices confirmed heparin colocalization on oligomer 
collagen fibrils and its retention after washing for 24 h (Figure 20 B and C). Such a 
uniform spatial distribution of heparin in collagen and its intercalation in collagen fibrils 
has been reported in previous studies [330, 348].  
The results obtained here are important because they demonstrated for the first time the 
effect of various concentrations of heparin on polymerization and visco-elastic properties 
of oligomeric collagen. Based on these results, we selected 1 μg/ml concentration of 
heparin for further design of VEGF retention system from oligomer, to preserve the 
oligomer polymerization and viscoelastic properties while enabling VEGF retention. 
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3.4.2 VEGF loading 
Because of the reported strong affinity of VEGF 189 for ECM, and its beneficial role in 
promoting vascularization in vivo, we incorporated VEGF 189 in our design strategy to 
enhance vascularization potential of oligomer implants. VEGF dose was then carefully 
chosen because of the evidences that over dosage of VEGF therapy  can result in an 
imbalance in angiogenic signals, leading to dysregulated vasculogenesis [364, 365] and 
hemangioma-like assemblies [364, 366].  The amount of VEGF 189 used in this study 
(0.5 μg/ml, or 0.125 μg  per implant) was chosen based on previous range of 
concentrations of VEGF reported in similar assays that showed enhanced vascularization 
effects in vivo either with heparin [64, 98, 307-311] or without heparin [205, 317, 339-
344]. For loading of VEGF to oligomeric matrix, we adopted admixing approach again, 
where 0.5 μg/ml VEGF189 was added along with 1μg/ml heparin in the neutralized 
oligomer solution and polymer self-assembly was induced at 37°C. Retaining both the 
heparin and VEGF in collagen matrix was thus achieved through single step.  
Since rapid, unregulated exposure of freely diffusible VEGF has been previously reported 
to cause excessive but abnormal, unstable blood vessel growth [89, 367], we washed all 
heparin and VEGF-containing oligomer implants for 24 h to remove any unbound 
heparin and VEGF. The washing step resulted in loss of about 74% of heparin as 
reflected by the results of DMMB assay for 1 μg/ml heparin-containing matrices. 
Therefore, we suspected that the final quantity of VEGF remaining in the implants would 
be very low. To quantify the exact amount retained in samples, we adopted LC-MS/MS 
technique due to its higher sensitivity than ELISA method (Sensitivity of full MS was 
500 fg buspirone on mass spectrometer column with signal to noise ratio of 100:1, while 
sensitivity of standard Quantikine ELISA kit assay is 9 pg/ml). The samples were 
enzymatically digested into peptides that were separated by high pressure liquid 
chromatography (HPLC) and introduced into a mass spectrometer (Q Exactive™ HF 
Hybrid Quadrupole-Orbitrap MS (Thermo Scientific, Waltham, MA) for fragmentation 
and sequencing to identify the parent proteins. However, the large presence of collagen in 
the samples obscured the VEGF detection in samples (data not shown).   To determine 
whether the VEGF remaining in oligomer implants was able to promote higher 
vascularization in vivo, it was therefore thought  to assess the effect of oligomer alone 
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(without heparin or VEGF) on CAM, followed by its comparison with the VEGF and 
heparin-infused implants. The results of this study are discussed in the following section. 
3.4.3 Evaluation of oligomer implant's vascularization potential in CAM assay   
To evaluate the vascularization potential of oligomer matrices in CAM, we implanted 
oligomer constructs on CAM at embryonic day 9, and after 3 days of incubation, we 
scored the CAM vessel density and distribution around the implants. The vascular 
response was also evaluated for occurrence of any tortuous, irregular, or fine, brush like 
vessels, as it could be an indication of abnormal and leaky vessel formation [89, 368]. 
Furthermore, to evaluate the vascular ingrowth from CAM into the implants, we 
performed histology and H&E staining on transversally cut implant samples that allowed 
us to envision both capillary formation and cellularization in the internal sections of the 
implants.  
3.4.3.1 Validating functionality of oligomer implants on CAM 
The first goal was to validate the suitability of oligomer constructs for implantation in 
CAM, and evaluating their vascularization potential in CAM, as compared to the 
commercial Integra collagen samples, and paper disc samples. Integra collagen used in 
this study was an absorbable wound dressing sponge made of collagen obtained from 
bovine deep flexor (Achilles) tendon, and it was chosen for comparison in this study 
since it is FDA approved and has been used successfully in clinical trials for treating 
wounds [369, 370]. 
Results of 3 day implantation on CAM demonstrated that 3 mg/ml oligomer induced 
higher vascular response on CAM compared to the Integra collagen implants or paper 
disc samples (Figure 22). Histology results further provided evidence that oligomer 
implants supported cell invasion from CAM into the collagen region in just 3 days after 
implantation. Cell infiltration was also found in Integra samples. However, large empty 
spaces were characteristic of Integra collagen, as opposed to uniform, dense fibrillar 
nature of oligomer sample. CAM cells invading the paper disc sample showed apoptic 
morphology, which can be attributed to the absence of collagen matrix that provides 
essential mechanical support and biological signaling for cellular growth and 
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proliferation. The higher induction of vascular response on CAM while maintaining cell 
infiltration as shown by oligomer implants, established them as suitable material for 
further vascularization study. 
3.4.3.2 Low fibril density heparinized oligomer implants promoted enhanced 
vascularization in CAM 
Having established suitability of oligomer implants in inducing vascularization on CAM, 
we next evaluated whether heparin and VEGF addition to oligomer implants enhanced its 
vascularization ability. Results indicated that heparinized oligomer implants containing 
VEGF induced highest vascular response on CAM among all groups (Figure 23). This 
enhancing effect of heparin and VEGF  has been observed previously, both in vitro [309, 
355] as well as in vivo [98, 310] although the time required for vascular effect was 
reported to be higher than 3 days. Moreover, these studies incorporated heparin in 
collagen matrices through EDC/NHS chemical cross-linking for VEGF retention. Here 
we obtained improved vascularization results through simple admixing of heparin and 
VEGF in oligomer, in an accelerated period of 3 days. 
The non-heparinized oligomer implants containing free VEGF also demonstrated 
angiogenic activity on CAM, however, the vessels formed around this group of implants 
were either brush like, or tortuous, indicating an abnormal vessel development. Such 
abnormal vessel development could be a result of passive, uncontrolled release of VEGF 
out of the oligomer implants. Similar to these findings, previous reports have indicated  
formation of chaotic capillary plexus in vivo in response to freely diffusible VEGF 
released from fibrin matrices, while matrix-bound VEGF induced formation of highly 
organized, functional vessels in CAM [89, 371].  
It addition to VEGF loaded implants,  heparinized oligomer implants without VEGF 
(Coll+Hep) also induced a vascular response on CAM, although it was weaker than 
Coll+Hep+VEGF group. The positive angiogenic effect of heparin by itself on CAM 
vasculature has been reported previously [372-374]. In the absence of exogenous growth 
factors, modification of collagen with heparin was found to increase neovascularization, 
possibly by potentiating endogenous growth factors present in vivo [59, 64, 98]. This 
positive effect of heparin could have been due to  its role in protecting cell secreted 
VEGF from degradation [192], and upregulating VEGF activities by enabling its binding 
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to the  KDR and Flt-1 receptors [375]. Finally, the non-heparinized oligomer implant 
(Coll), showed a vascular response that was significantly lower than either VEGF or 
heparin or both VEGF and heparin loaded matrices. Together, these results highlight the 
potential of heparin in retaining VEGF in oligomer implants and upregulating its 
activities on CAM. These results also convey the importance of controlled VEGF release 
essential for formation of normal vasculature on CAM, which was achieved in our system 
using simple affinity based retention of VEGF. 
3.4.3.3 Enhancing CAM vascularization through high fibril density implants  
The vascularization potential of low-fibril density oligomer implants can be beneficial in 
cases such as small injuries or as acute wounds, where the low mechanical properties of 
the implants could suffice tissue healing for a short period of time. However, in cases 
such as chronic wounds, where the regeneration of new tissue is difficult due to high 
level of proteases [189, 376], the implants would be required to last longer to support and 
accelerate new capillary ingrowth into the implant. For this purpose, oligomer implants of 
high fibril density can offer a potential solution due to their characteristic  higher 
mechanical strength and resistance to proteolytic degradation [116]. Moreover, the 
increased fibril-density would have a positive effect on retaining the encapsulated growth 
factors [4], due to their enhanced fibril density (reduction in pore size) [183]. Therefore, 
with an objective to provide stronger mechanical support and enhanced VEGF retention, 
we prepared high fibril-density 20 mg/ml oligomer implants loaded with heparin and 
VEGF and evaluated their ability to accelerate local vascularization in CAM after 3 days 
of implantation. 
Results of 20 mg/ml implants (Figure 24) were similar to 3 mg/ml implants, where 
heparinization and VEGF incorporation of the implants led to significantly higher 
vascularization. VEGF-containing implants without heparin led to brush-like or 
tortuous/abnormal vessel response again, emphasizing that uncontrolled VEGF release 
had undesirable consequences on normal vasculature development of CAM. Heparinized 
implants without VEGF showed a weaker vascular response than with VEGF loading. 
Oligomer implants without heparin or VEGF incorporation showed significantly lower 
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vascular response. These results corroborated the advantages of incorporating heparin 
and VEGF together in oligomer scaffolds, to achieve enhanced neovascularization. 
Apart from maintaining their ability to promote vascularization, another remarkable 
result demonstrated by the 20 mg/ml implants was their ability to retain their shape and 
exposing large area for growth of CAM vasculature even on day 3 of implantation. In 
fact, the 20 mg/ml implants retained largest cross-sectional area among all the collagen 
implants tested in this study (Table 5), which can be a result of the high mechanical 
integrity of these constructs. Most collagen implants without the aid of exogenous 
crosslinking suffer from the drawback of low mechanical integrity, rapid degradation and 
fast diffusion of growth factors [4, 5]. Therefore, considering the lack of exogenous 
crosslinking in our study, the results obtained here in terms of preservation of mechanical 
integrity, retention of VEGF and promotion of vascularization on CAM were found to be 
impressive.   
3.4.4 Cellularization of oligomer implants  
The induction of high vascular response around both 3 and 20 mg/ml oligomer implants 
containing heparin and VEGF informed us about the effect of heparin and VEGF delivery 
from oligomer on CAM vasculature. However, for clinical success of tissue-engineered 
scaffolds, along with promotion of vascularization around the implant, growth of micro 
vessels within the implant is crucial to enable survival of cells in the core of the scaffold 
[296]. CAM assay allows the advantage of envisioning such a microvasculature growth 
inside scaffolds that can be separated from the surrounding CAM vasculature, as these 
new micro vessels grow inside the scaffolds against gravity [326, 377, 378]. We 
evaluated the ability of oligomer implants to draw in such micro vessels, through H&E 
based staining of transverse histological sections of the implants (Figure 26).  
Results revealed that non-heparinized implants supported cellular infiltration, however, 
these cells were not aligned towards any particular direction.  VEGF loaded non-
heparinized induced formation of several capillaries on CAM adjacent to the implant 
periphery, but not within the implant. In contrast, heparinized oligomer implants loaded 
with VEGF induced formation of several capillaries inside the implants, clearly showing 
the benefit of adding heparin in upregulating vasculature inside the oligomer implants. As 
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proposed in previous studies [64, 97, 349, 379], this upregulation of neovasculature 
inside collagen implants could have on account of the prolongation in VEGF's biological 
activity [202, 380] and  more efficient binding of VEGF to its receptors in presence of 
heparin [355, 380].   
Another outstanding result of implanting heparinized VEGF-containing oligomer on 
CAM was highest invasion of CAM cells within the implants. These cells also displayed 
remarkable alignment towards the implant, which could be a result of VEGF signaling 
gradient present across the boundary of oligomer implant and CAM. Physiologically, 
such a VEGF gradient  in hypoxic or diseased tissues [381],  exercising skeletal muscle 
[381, 382], and wounds [383] has been shown to be responsible for attracting endothelial 
sprouts towards hypoxic regions. A putative gradient of VEGF formed in collagen 
implants has also been reported previously to be responsible for cell recruitment in other 
studies involving VEGF [341] and other growth factor delivery through collagen 
implants [384]. Therefore, the increased infiltration of CAM cells within heparinized, 
VEGF-containing oligomer implants obtained here could have been a consequence of 
presence of such a concentration gradient created across the interface of oligomer 
implants and CAM.   
In the present study, the process of vascularization of heparinized oligomer matrices was 
seen to be accompanied by a remodeling of the matrix (Figure 26 D and H), and this 
process is also known to occur in physiological healing of wounds [385]. The 
physiological  remodeling of wound includes degradation of the collagen through matrix 
metalloproteinases (MMPs) [386] secreted by infiltrating fibroblasts that then deposit 
newly synthesized collagen [192, 387]. In our CAM study, the cells infiltrating in 
oligomer matrix could be participating in such activities, subsequently remodeling the 
collagen matrix they resided in, generating their own micro-environment and, 
proliferating, differentiating and attracting other cells inside the collagen [384].  
While several studies reported that modified collagen implants increased in 
neovascularization on the CAM surface [64], very few [334] have documented actual 
neovascularization inside the collagen matrix  of the implant. Kilarski et al. [334] 
reported that neovessels  found in their collagen matrix were contained within the 
expanding CAM tissue that eventually replaced the provisional matrix and there was a 
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clear demarcation between the ingrowing tissue and the implanted gel, implying that the 
neovessels entered their collagen gel as a part of ingrowing CAM tissue buds, but not as 
independent entities. In our model however, we found capillaries both inside the 
ingrowing CAM tissue as well as inside collagen as separate entities, in addition to the 
capillaries on CAM tissue on periphery of the implant.  Furthermore, such cellularization 
and neovascularization was obtained in just 3 days, while several collagen implant 
studies have required several days for cellularization of their constructs in either CAM or 
rat subcutaneous implantation studies [64, 98, 307-311].  In the light of the current state-
of-the-art collagen induced vasculature on CAM, oligomer constructs that demonstrated 
this distinct microvasculature as well as cellularization inside them appears very 
promising for promoting tissue regeneration and integration with the host tissue. 
3.5 Conclusion 
Physiologically, the process of vessel formation takes place in the ECM, that 
constitutes a dynamic 3D microenvironment of cells, providing the instructive 
biomechanical and biomolecular signaling required for morphogenesis. The ECM is the 
natural biological material, which with the help of molecules such as heparin sulphate 
proteoglycans or heparin, regulates the sprouting of new blood vessels, and their 
stabilization, leading to restoration of functional blood circulation into ischemic tissues. 
Inspired by this role of ECM and heparin in spatio-temporal regulation of growth 
factors in vivo, we designed a physiologically relevant collagen implant from self-
assembling oligomer molecules that can control the local presentation and release of 
VEGF at the site of implantation. We leveraged heparin's affinity for oligomeric 
collagen molecules and VEGF189 for this purpose, enabling a single step local 
retention of VEGF189 in the oligomer implants for promotion of vascularization.  
We then validated the functionality of the oligomer implants in promoting vascularization 
and cell infiltration in vivo, through the use of simple and reproducible CAM assay. 
When compared and contrasted with paper discs, Integra collagen, and non-heparinized 
as well as free VEGF loaded implants, we found a clear benefit of heparin addition in 
oligomer implants that resulted in formation of robust neovascularization in an 
accelerated time period of 3 days. We also demonstrated that the vasculature response 
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can be controlled by altering contents (heparin and VEGF loading) as well as the fibril 
density of oligomer implants. VEGF loaded implants without heparin led to formation of 
tortuous vessels, corroborating the dangers of uncontrolled VEGF therapy. In contrast, 
heparinized implants loaded with VEGF demonstrated improved and stable vasculature 
formation both around and within the implants, signifying the importance of heparin for 
controlling the VEGF release.  
While CAM assay allowed us to evaluate the viability of oligomer implants as angiogenic 
biomaterial, in a rapid, simple, and low-cost in-vivo setting, it should be noted that this 
model system is an intermediate step between a cell culture and a large animal studies or 
more complex mammalian model. Therefore, the positive results of enhanced 
vascularization through heparinization of oligomer implants obtained in this study must 
be tested in a large animal and mammalian model, and the differences between avian and 
mammalian biology should be taken into account before applying any conclusions from 
CAM assay to a mammalian model [388]. 
Finally, it is worth mentioning that the implants designed in this work were fabricated 
without the use of exogenous crosslinkers, and the heparin quantity chosen for loading 
VEGF did not affect oligomer collagen self-assembly. Consequently, the designed 
implants retain collagen’s multi-scale structural features and inherent biological signaling 
capacity while promoting microvasculature formation inside the implants in an 
accelerated manner. Accelerated vascularization in turn can shorten the time of 
cellularization of constructs, decrease the risk of infection, and result in faster tissue 
integration and regeneration or healing of the affected tissue [389], thus providing an 





CHAPTER 4. CONCLUSION & FUTURE WORK 
4.1 Conclusions 
There is a significant challenge in the design and manufacture of multifunctional biograft 
materials capable of providing tunable molecular delivery due to the poor mechanical 
properties, rapid proteolytic degradation, and inability of collagen formulations to 
demonstrate physiologically relevant self-assembly. This work attempts to address these 
limitations with the use of novel self-assembling collagen-fibril biograft materials. 
Overall, we achieved a successful design and development of self-assembling, 
multifunctional 3D collagen-fibril biograft materials with a broad range of tunable 
physical and molecular delivery properties. More specifically, collagen polymers 
specified by their intermolecular crosslink composition and self-assembly capacity were 
used to customize and design materials in terms of 1) collagen fibril microstructure and 
2) proteolytic degradability. Furthermore, to increase local retention of biomolecules such 
as vascular endothelial growth factor (VEGF) in collagen, we successfully employed 
affinity based strategy that exploited the VEGF-binding and collagen-binding capacity of 
heparin. The functionality of collagen biograft materials was demonstrated in an in-vivo 
CAM model, where enhanced local retention of VEGF led to increase in 
neovascularization and cell infiltration of collagen biografts. 
Specifically in Chapter 2, we found that when compared with the conventional collagen 
monomer (e.g., atelocollagen, telocollagen) matrices, oligomer matrices exhibited 
uniform, highly branched fibril ultrastructure and possessed higher resistance to 
proteolytic degradation. As a result, oligomer matrices exhibited size-dependent and 
sustained molecular release while conventional telocollagen matrices showed burst 
release for small as well as large sizes of FITC-dextrans.  Fibril microstructure and 
proteolytic degradability was also significantly affected by varying the collagen polymer 
building blocks (e.g. oligomer, telocollagen and atelocollagen) used for self-assembly.  
Most contrasting release profiles were obtained using oligomer and atelocollagen 
building blocks, with oligomer showing most sustained release while atelocollagen 
showing most rapid release in both absence and presence of collagenase. Molecular 
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release of both small and large molecules was further fine-tuned by combining oligomer 
and atelocollagen in different percentages. Increase in oligomer percentage extended the 
molecular release time observed through mixed matrices. An enhancement in molecular 
retention was further achieved by increasing collagen fibril density that also improved 
resistance of materials against collagenase. Collectively, through these results, we 
demonstrated successful development of collagen fibril biografts that could be tuned in 
terms of their fibril microstructure and proteolytic degradability for providing tunable 
molecular release of wide range of molecular sizes. 
In Chapter 3, we validated the functionality of these collagen biografts for promoting 
local vascularization and cell infiltration using an established in-vivo CAM assay through 
controlled VEGF delivery. Here, to increase local retention of VEGF in collagen, we 
employed affinity based strategy that exploited the VEGF-binding and collagen-binding 
capacity of heparin. Results showed a clear benefit of adding heparin to oligomer 
matrices, leading to an increased vascular response on CAM and enhanced 
neovascularization as well as cell infiltration of the implants. We further demonstrated 
that response was dependent on the absence or presence of heparin and VEGF in 
oligomer implants and the fibril density of oligomer implants. VEGF loaded implants 
without heparin led to formation of tortuous vessels, corroborating the potential dangers 
observed with uncontrolled VEGF therapy by researchers in the past. In contrast, 
heparinized implants demonstrated stable vasculature response both around and within 
the implants, signifying the importance of heparin for controlling the VEGF release. 
Overall, the heparinization prevented uncontrolled VEGF release from collagen and led 
to a remarkable increase in neovascularization and cellularization of the implants in a 
short period of 3 days.  
Altogether, this work indicates that the collagen polymers specified by their 
intermolecular crosslink composition and self-assembly capacity can be used effectively 
to fashion a broad range of multifunctional collagen-fibril biograft materials with tunable 
physical and molecular delivery properties in absence of excessive processing and 
exogenous crosslinking. These highly porous collagen materials comprise D-banded 
fibrils, resembling those found in tissues, and maintain their inherent biological signaling 
properties. The remarkable ability of these designer implants in supporting enhanced 
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neovascularization and cellularization of the constructs in an accelerated period indicates 
their strong potential as an ideal platform for integrated tissue engineering, regeneration 
and molecular therapy design.  
4.2 Future Work 
Since the motivation to develop collagen based tissue engineering implants is to address 
unmet clinical need of soft tissue replacement, the ultimate success in its clinical 
translation will depend on an interactive, back and forth, “bedside to bench and back 
again” approach that has recently emerged [390]. For the designer collagen biografts 
studied in this work to reach patient care in the near future, such an approach is of utmost 
importance. Many indispensable steps should be met with in this approach, the first and 
foremost being in-vivo trials using small and large animal models to evaluate safety and 
efficacy of the biografts for desired clinical need.   
A specific example of such a clinical need where the collagen biografts developed in this 
work could be applied, is the treatment of chronic wounds such as diabetic ulcers. As 
mentioned in first chapter of thesis, diabetic ulcers result in significant morbidity, 
prolonged hospitalizations, and enormous healthcare costs. Therefore, the efficacy and 
safety of collagen biografts to heal diabetic ulcers could be shown using non-healing 
wounds in a diabetes-induced animal model [391]. Among the various animals that can 
be used for this purpose, such as rabbits, dogs, goats, sheep, or pigs, we propose the pig 
model studies, because of their known anatomical and physiological similarities to 
humans[392]. Diabetes can be induced in pigs via streptozotocin injection[391]. Full 
thickness wounds can then be introduced in pigs to create diabetic ulcers. Collagen 
biografts will then be implanted on the wounds and untreated wounds will serve as 
controls.  
The pig experiment will be carefully designed to include all variables in the biograft and 
each variable will be tested separately. As required by law, the animal research protocol 
would then be submitted to the Institutional Animal Care and Use Committee (IACUC) 
for approval.   The outcome of the pig model study would be immensely valuable in 
determining the safety and efficacy of the collagen biografts, and would pave the way 
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APPENDIX A. TYPE I COLLAGEN BASED DRUG DELIVERY 
FORMATS 
Table A: Examples of Type I Collagen-based Drug Delivery in Research 
 
1. Gels  
Molecules 
delivered 
















Physical: Direct Admixing in 
collagen solution, then allowing 
collagen to polymerize into gel 




Facilitating tissue repair Chemical: Covalent binding to 




Smooth Muscle Cell 
Proliferation  
Chemical: Chimeric collagen 
binding domain based 
attachment  
2. Shields 
Plasmid DNA [129] Gene therapy for healing after 
glaucoma surgery 
Physical: Plasmid absorbed into 
the collagen shield  







Antibiotic therapy through 
collagen contact lenses 
 
Keratoplasty treatment  
 
 
Physical: Presoaking collagen 





Factor VEGF [400] 
 
Nifedipine [401] 
Useful for paracrine assays 
and angiogenesis 
 
Transdermal delivery devices 
for wound dressings 
Physical: Admixing  in collagen 
gel followed by vitrification 
 
Physical: Mixing in alginate and 




Table A (continued) 
 
It can be seen from above table that the versatility of collagen lends itself well to a 
variety of medical applications including but not limited to wound care, oral surgery, 
cardiovascular systems, neurology, urology, and orthopedics. The formats of collagen 
used in these applications are many, and selective examples are described below. 
Sponges: Collagen sponges were originally developed as wound dressings due to 
their ability to absorb large quantities of tissue exudates, adherence to wet wound bed 
with preservation of low moist environment and shielding against mechanical harm and 
secondary bacterial infection [406]. Growth factors have been coated on collagen sponge 
to give recovery from dermal and epidermal wounds [138, 139]. Collagen sponges are 
generally prepared by lyophilizing aqueous collagen preparations [4] which yields 
collagen sponges with high porosity and fibril interconnectivity. The porosity of the 
lyophilized collagen can be altered by varying the collagen concentration and the freezing 
rate, which allows for some degree of control over the design of the sponge [407]. 
4. Microspheres/nanoparticles    
Retinol, tretinoin, 
or tetracaine and 
lidocaine in free 
base form [402] 
Carriers for lipophilic drugs 
 
Physical: Drug encapsulated by 
emulsion into  cross-linked 




Delivery to the ocular surface 




suspended in methyl cellulose 
5. Sponge 
Retinoic acid RA 
[404] 
 
Endothelial regeneration in 
prosthetic bypass grafts 
Chemical: Chimeric domain 














Physical: Lyophilized sponge 
rehydrated and soaked in 




Another method of loading lyophilized sponge, apart from coating them with drug 
solution, is to soak the sponge in aqueous drug formulations prior to implantation. For 
example, porous collagen sponges have been soaked in antibiotic solutions (e.g., 
gentamicin) [142, 143] and in growth factor solutions (e.g. rhBMP) for delivery to tissue 
of interest [145]. In addition, collagen can be combined with other materials like such as 
elastin [408], fibronectin and hyaluronate [409] or glycoaminoglycans [410, 411] to aid 
in the delivery of drugs which do not interact well with collagen. The starting collagen 
material can be cross-linked with agents like glutaraldehyde and dehydrothermal 
treatments (DHT) in order to achieve highly resilient materials [410, 411]. However, the 
use of such cross-linking agents is not always effective as discussed in section 6. Sponges 
also suffer from the problem of releasing the entrapped factors quickly [159], giving a 
burst release profile in most cases [4].  
Gels: Collagen gels are primarily used in aqueous injectable systems that are 
initially liquid but solidify after administration to the tissue. In situ polymerization 
methods offer an advantage of injectability and spatial control with better mechanical 
properties over other collagen-based devices such as implantable collagen sponges or 
sheets. For most gel formulations, the drug is admixed or physically entrapped with 
collagen in liquid form at a certain ratio, and then allowed to gel when the temperature is 
raised to 37 °C (body temperature), as is the case with drugs such as pilocarpine, TGF-β, 
doxorubicine and ketorolac (Table 2) [393-396]. Although such collagen gel systems 
show promise in drug delivery, their open pore structure cause diffusion-dominated 
release, which is undesirable due to little or no control over drug release rates. 
Shields: Collagen shields have been primarily used as therapeutic devices for 
ophthalmological conditions such as plasmid delivery for glaucoma treatment or contact 
lenses to promote corneal epithelial healing and deliver hydro soluble drugs [129]. 
Shields typically start in a dehydrated form and have to be soaked with drugs in liquid 
solution prior to application. The thin collagen films conform to the shape of the cornea 
when applied to the eye and are able to provide sufficient oxygen transmission, as well as 
act as short term bandage lenses [412]. As the shields dissolve, they provide a layer of 
collagen solution that lubricates the surface of the eye, minimizes rubbing of the lids on 
the cornea, and fosters epithelial healing [65]. However, some disadvantages still limit 
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the application of collagen shields such as incomplete transparency, slight discomfort, 
complex insertion technique, and short period of working before dissolution. For 
mechanical strength imparting reason, cross-linking is performed on shields already 
loaded with drugs, but that endangers the chemical integrity of the active substance [160].  
Microspheres: Collagen microparticulate systems have been used for 
encapsulating number of antibiotics, steroids, growth factors, and hydrophilic and 
hydrophobic drugs for therapeutic purposes due to their small particle size, large surface 
area, and ability to disperse in water to form colloidal solutions [65]. Microspheres can 
provide regulation of release by controlling the shell material and protection of drug until 
its delivery is needed [413].  Moreover, microspheres can create gradients in the 
concentration of growth factors that can direct cell migration, create patterns of cell 
differentiation an direct tissue organization into complex structures such as branching 
networks of vascular systems [107].  
Despite many successful studies on collagen microspheres, the transition to 
collagen as the primary biomaterial for microsphere technology is hindered by limitations 
in manufacturing material, methods, and use of solvents due to risks of collagen 
denaturation. Most of the methods of formulation are tedious, requiring that each step 
(i.e. droplet generation, gelation, and extraction) be performed separately [414]. 
Furthermore, microsphere prepared have to be cross-linked exogenously in most cases, in 
order to avoid the possibility of losing the mechanical integrity and shape of device, but 





APPENDIX B. STATE-OF-THE-ART METHODS OF TUNING 
COLLAGEN BASED MOLECULAR RELEASE 
Table B: Strategies of tuning molecular release from collagen based materials and 
their limitations 















30 days [317] Detrimental effects 
on cells and tissues, 
such as cytotoxicity 
or tissue calcification; 
 
Release requires 
hydrolysis of a 
linking bond which is 
different from in-vivo 
proteolytic 
degradation; 
   
Crosslinking with 
additives increases 
complexity of system 
Crosslinking reagents 





growth factors and 
other bioactive 
















e (NHS).  




and PVP capped 
ZnO (ZnO/PVP) in 
























and film with drug 








5 days [141] Succinylated 
collagen gels do not 
appear to have a long 
lifetime in vivo, 
usually disappearing 
within 24 h 




























can be difficult to 
control, produce poor 
reaction yields, and 
even compromise the 
biochemical features 






















of interest  
Heparin basic fibroblast 
growth factor 
(bFGF) 
10 days [94] Binding interactions 
are specific to each 
drug and hard to 
predict; 
Very little tuning if 
the binding 


















Hybrid scaffolds of collagen 
and poly (lactic-co-glycolic 
acid) microbeads were 
prepared by introducing 
insulin-releasing poly (lactic-
co-glycolic acid) microbeads 
into collagen porous scaffolds. 
Pore structure was controlled 
using ice particulates. 



















difficult   
Collagen–
hydroxyapatite scaffolds 
combined with either alginate 
or poly(lactic-co-glycolic acid) 
(PLGA) microparticles 
rhBMP-2 28 days [420] 
Addition of BMP-2 into soft 
PEG hydrogels before infusion 













60 hrs [422] 
collagen impregnated with 









in 72 hrs 
[423] 
lyophilizing  solution of 
suspended  PLGA 
microparticles in a collagen 
dispersion 
gentamicin 7 days [424] 
Drug containing liposome 

















(CBD)   
Fusion protein consisting 
of hepatocyte growth factor 
(HGF; an angiogenic 
factor) and a collagen-
binding domain (CBD) 
polypeptide of fibronectin 





























are bound to 
collagen via thermally 
induced annealing that 
induces CMP strand 
invasion and CMP-
collagen triple helical 
hybridization 








Collagen gel was  dried for 
2 weeks to convert into a 
rigid glass-like material, 
which was rehydrated with 
PBS containing VEGF 





After gelation, collagen 
membranes were formed 
by vitrification for 2 days, 
followed by rehydration 



















Collagen content varied 
from 1.5% to 2.0% and 2.5 
%,  pexiganan release from 
collagen was found to be 
extended from 24 h to 48 h 
























(COLs) was used and 
collagen concentration 
varied from 100 mg/ml to  












42 days [204] 
Concentration of type I 
collagen hydrogels was 
varied from 1.5 to 4.5 
mg/ml; drug interaction 
also played a role in tuning 
the release 
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